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Abstract 
Kojic acid (KA) is a secondary metabolite and divalent metal chelator that is widely used in the 
beauty industry as a skin lightener. However, KA toxicity is not well-established in humans. This 
study aimed to determine the toxicity of KA by assessing oxidative stress, nuclear factor kappa B 
(NFκB) signalling, and mitogen-activated protein kinase (MAPK) signalling in human hepatoma 
(HepG2) cells following 24 h exposure. Cell viability was assessed using the methylthiazol 
tetrazolium (MTT) and crystal violet assays. To confirm cell death, apoptosis (caspase -8, -9, -3/7 
luminometry), and Lactate dehydrogenase (LDH) leakage were assessed.  Oxidative stress (TBARS), 
DNA damage (8-OHdG), and protein oxidation (protein carbonyls assay) to determine macromolecule 
damage. An assessment of inflammatory and oxidative stress markers were carried out using mRNA 
expression (GPx, NFκB, IκB; qPCR) and miRNA expression (miRNA-29a, miRNA-29b and miRNA-
155; qPCR). Protein expression of nuclear factor erythroid-2 factor-2 (Nrf2), phospho-Nrf2 (ser40), 
catalase (CAT), c-Jun-N-terminal kinase (JNK), p38, phospho-Sirtuin 1 (ser47) (phospho-sirt1), 
NFκB, phospho-NFκB (ser536), and activator protein 1 (AP-1) were assessed using Western Blot in 
HepG2 cells. KA decreased cell viability in HepG2 cells and elevated the activities of caspase -9 (p < 
0.0001), caspase -8 (p = 0.0003) and caspase 3/7 (p < 0.0001) at lower concentrations [4.22 & 8.02 
mM] which served as confirmation of apoptosis. Necrosis at the higher concentration [12.67 mM] was 
confirmed by the presence of LDH leakage indicating membrane damage. Increased cell death was 
further correlated with increased miRNA-29b expression (p = 0.009), a miRNA responsible for 
elevated apoptotic activity. Adenosine Triphosphate (ATP) production was increased significantly at 
12.67 mM (p < 0.0001), while oxidative stress (Malondialdehyde (MDA) levels) was increased 
significantly at 4.22 mM (p < 0.0001). Macromolecules are susceptible to damage in the presence of 
oxidative stress. Due the elevation of MDA levels, DNA damage and protein oxidation assays were 
carried out. Protein carbonyls were significantly decreased (p < 0.0001), suggesting a potential 
cytoprotective effect. Due to the presence of oxidative stress, Nrf2, is activated and is responsible for 
the transcription of antioxidant genes. This was illustrated by an increase in activated Nrf2 at lower 
concentrations (4.22 & 8.02 mM), whilst at higher a concentration (12.67 mM) decreased phospho-
Nrf2 (p > 0.0001). CAT was decreased significantly (p = 0.0002) and GPx significantly increased at 
lower concentration [4.22 mM] (1.51-fold). A key function of the MAPK pathway is the initiation of 
stress-activated protein kinases, p38 and JNK, in response to oxidative stress. KA significantly 
increased, p38 at lower concentration (p = 0.0011) and significantly decreased JNK1 (p = 0.0039) and 
JNK2 (p < 0.0001) activity. Regulation of reactive oxygen species (ROS) production by Sirt-1 occurs 
via the alteration of immune responses through NFκB signalling and AP-1. Inflammatory mediators, 
phospho-Sirt1 was significantly decreased (p < 0.0001), while AP-1 expression was elevated (p = 
0.0003). The decrease in phospho- Sirt1 resulted in decreased phospho- NFκB expression (p < 
0.0001). To further illustrate inflammation repression and alteration in MAPK signalling, MiRNA-155 
expression was increased (p = 0.0018). There was elevation of miRNA-29a expression (p = 0.0002) 
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which is in agreement with repressed inflammatory responses reflected by decreased NFκB 
expression. KA treatment resulted in increased MDA levels and antioxidant responses. MAPK 
signalling was elevated in response to oxidative stress suggesting the involvement in cell death, whilst 




















Kojic acid (KA; 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one), is a fungal metabolite produced by 
Aspergillus and Penicillium species (Parrish et al., 1966). KA is a hydrophilic acid and a recognised 
chelating agent that is widely used in the medicinal, cosmetic and food industry (Azami et al., 2017), 
known to inhibit tyrosinase activity in melanocytes leading to the reduction of melanin and lightening 
of skin pigmentation (Choi et al., 2012).  
 
Toxicity studies by Rodrigues et al. (2011) found that  KA’s ability to produce reactive oxygen 
species (ROS) enhances the phagocytic activity of mice peritoneal cells leading to cell damage. In 
contrast, KA was found to have an antioxidant effect on cells by scavenging ROS in leukocytes in 
vitro (Niwa and Akamatsu, 1991). In vivo, KA studies found increased lipid peroxidation, expressed 
as elevated MDA levels, in liver homogenates (Kotyzova et al., 2004). Oxidative stress is a result of 
the imbalance between antioxidants and oxidants (free radicals). The molecular oxygen can react to 
form products such as water (H2O), hydrogen peroxide (H2O2), and superoxide anions (O2
-
). The 
equilibrium required for the normal functioning of biological systems is altered when oxidants exceed 
the cells antioxidant capacity (Ott et al., 2007).  Macromolecules exposed to excess ROS form DNA 
adducts, protein carbonyls, and are prone to lipid peroxidation (Wiesmüller et al., 2002, Cooke et al., 
2003, Dalle-Donne et al., 2003, Ayala et al., 2014). 
The increase of ROS results in an antioxidant response by nuclear factor erythroid-2 related factor 2 
(Nrf2). Majority of ROS is produced in the mitochondria (Murphy, 2009).  Nrf2 is termed the master 
regulator of antioxidant responses due to its function in the transcription of antioxidant genes, namely 
superoxide-dismutase 2 (SOD2) and catalase (CAT). These enzymes play key roles in the alleviation 
of oxidative stress (Basak et al., 2017). O2 is converted by SOD2 to H2O2 and later decomposed by 
CAT to hydrogen peroxide (H2O2) and O2. Dysregulations in the antioxidant response have been 
linked to several diseases (Liguori et al., 2018).  
ROS acts as a secondary messenger which initiates an immune response. KA inhibits tyrosinase 
activity; hence, the mitogen-activated protein kinase (MAPK) pathway could be a potential target. 
ROS has been found to activate the MAPK signalling pathway to initiate cell death due to toxic insult 
(Kim et al., 2014). The MAPK family comprises of serine/threonine protein kinases, namely, 
extracellular signal-regulated kinase (ERK), c-Jun-N-terminal kinase (JNK) and p38. The oxidative 
stress that cells experience can influence the MAPK pathway affecting the stress-activated protein 
kinases (SAPK), namely, JNK and p38. MAPK is responsible for the phosphorylation of transcription 
factors and cellular functions such as cell survival and cell death. The MAPK pathway has been 
implicated in the activation of Nrf2; however, the mechanism in which regulation is initiated remains 
elusive. Studies to date have favoured indirect phosphorylation of Nrf2 as a point of regulation by the 
MAPK pathway (Sun et al., 2009). Previous KA studies have shown that MAPK expression was 
17 
 
upregulated in injured Hypsizygus marmoreus as a response to the increase of oxidative stress. The 
expression of CAT was upregulated as well as extracellular ATP (eATP) as a stress signal to facilitate 
mycelial regeneration (Zhang et al., 2017). Previous studies have not investigated Nrf2 and MAPK 
signalling following treatment with KA in HepG2 liver cells. 
Immune responses result in the activation of the inflammatory pathway in the case of oxidative stress. 
Sirtuin 1 (Sirt1) interacts with MAPK proteins in the presence of oxidative stress. Sirt1 is a protein 
deacetylase, responsible for alleviating oxidative stress and promoting cell survival (Salminen et al., 
2013). Regulation of ROS production by Sirt1 occurs via the alteration of immune responses through 
nuclear factor kappa B (NFκB) signalling and activator protein-1 (AP-1) (Salminen et al., 2013, Xie et 
al., 2013a). Inflammation is a contributing factor to several pathologies. NFκB and IκBα (nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) are found in the 
cytoplasm; IκBα is phosphorylated and free for ubiquitin-dependent proteasome degradation while 
NFκB translocates to the nucleus for the transcription of pro-inflammatory cytokines (Yang et al., 
2012). KA has shown anti-inflammatory effects in transfected HaCaT keratinocyte cells (Moon et al., 
2001)  
MAPK proteins activate pro-inflammatory cytokines such as the tumour necrosis factor (TNF) family,  
and interleukin-1 (IL-1) to enhance AP-1 activity  (Shaulian and Karin, 2002). AP-1 is made up of 
dimeric basic region leucine-zipper (bZIP) proteins, Fos, Jun, Maf and ATF sub-families. Of the 
subfamilies, c-Jun (potent transcription activator) and Fos hetero-dimerize which allow for more 
efficient DNA binding activity. AP-1 participates in many processes in cells including cell 
proliferation ,  differentiation, inflammation and cell death (Fisher and Voorhees, 1998).  
MicroRNAs (miRNA’s) are a class of post-transcriptional repressors of gene expression (Reinhart et 
al., 2000). MiRNA’s play key roles in the regulation of inflammation, oxidative stress, immune 
response and cell death. Examples of these miRNA’s are miRNA-155, miRNA-29a and miRNA-29b. 
MiRNA-155 expression can repress NFκB and MAPK signalling (Wang et al., 2015). MiRNA-29a 
expression is also inhibited by NFκB and decreases apoptosis by targeting proapoptotic mediators 
such as bcl-2-like protein 4 (Bax), poly(ADP-ribose) polymerase (PARP), phospho-Fas-associated 
protein with death domain (phospho-FADD), cleaved caspase 8, and caspase 3 (Tiao et al., 2014). 
MiRNA-29b functions include the regulation of oxidative stress by increasing apoptosis and 
decreasing  cell viability (Hou et al., 2017). 
The level and duration of oxidative stress determines the degree of damage and the initiation of cell 
death. Apoptosis plays a key role in the maintenance of cellular homeostasis by removing injured 
cells. Apoptosis is executed via the intrinsic and extrinsic apoptotic pathways by caspases; initiator 
(caspase -8 and -9) and the executioner (caspase -3/7) (Elmore, 2007). KA has known functions in the 
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inhibition of cell proliferation and the reduction of tumour growth (Chen et al., 2013). Although KA is 
known to inhibit cell proliferation, little is known on its inhibitory mechanism. 
Research determining the effects of KA on oxidative stress, MAPK signalling, and inflammation have 
been established in some animal and human models, however, liver toxicity remains neglected. This 
study investigates the effect of KA on oxidative stress, MAPK signalling pathway and NFκB 
inflammatory responses in the human liver (HepG2) cell line. Results from this study provide insights 






















LITERATURE REVIEW  
1.1. Kojic acid 
Kojic acid (KA) is a secondary metabolite formed by aerobic respiration in several fungal species 
belonging to the genera Penicillium and Aspergillus (Parrish et al., 1966, Mohamad et al., 2010, El-
Kady et al., 2014). Several carbon sources are used in KA production, such as glucose, sucrose, 
arabinose, xylose, acetate, and ethanol (Burdock et al., 2001). There are several uses of KA in the 
agricultural, food, cosmetic, and medicinal industries. KA has been used as a pesticide and insecticide 
due to its antifungal and antibacterial properties (Lee et al., 1950, Beard and Walton, 1969, Uher et 
al., 1994, Kim et al., 2012, Wu et al., 2019). It inhibits melanin production to reduce skin conditions 
for example melasma (Bandyopadhyay, 2009). KA is also used to preserve food by preventing the 
discolouration of fruits and acting as a flavour-enhancing additive (Chen et al., 1991, Burnett et al., 
2010, Deri et al., 2016).  
1.1.1. Chemical structure of Kojic acid 
KA is known by the chemical nomenclature 5-hydroxy-2-hydroxymethyl-γ-pyranone (C6H6O4). KA 
was first discovered in 1907 in mycelia of A. oryzae, but the structure was later discovered in 1924 
(Beelik, 1956, Belsito et al., 2009). KA is a weak acid with a hydroxyl group on the C5 position of the 
heterocyclic structure (Fig 1.1). KA has an amylene oxide ring structure similar to that of glucose; 
however, the KA ring structure is stable. The compound structure allows for the formation of salts by 
the chelation of metals (Beelik, 1956, Saeedi et al., 2019). KA can form salts with metals such as 
sodium, copper, zinc, calcium, nickel, and cadmium (Coupland and Niehaus, 1987a, Saeedi et al., 
2019). This attribute has been exploited in the inhibition of melanin (Azami et al., 2017). 
KA was considered a mycotoxin due to its contamination of maize and poultry feed and co-existence 
with aflatoxins (Parrish et al., 1966, Souza et al., 2013). With the emergence of more research into 
KA, it was suggested that KA does not exhibit mycotoxin risks to human health (Bentley, 2006). The 
lack of research in some aspects of the efficacy of KA on human health may be the reason for KA's 






Figure 1.1 The chemical structure of KA derived from Aspergillus oryzae fungi. Chemical 
structure was drawn using PubChem Sketcher Version 2.4. 
1.2.2. Absorption, distribution, and metabolism of Kojic acid 
KA is absorbed and distributed in the body through the dermal, transdermal, and oral routes of 
exposure. An in vitro study by Sansho Seiyaku Co., Ltd determined that the percutaneous absorption 
of 2 mg/cm
3 
KA  administered to human dermatomed skin, with 16.98% of the administered KA  
percutaneously absorbed following 16 h incubation. This study was further validated in humans. 
Women who applied creams containing 1% KA to their skin for a period of 0.5, 1, 1.5, 3, 6, 12 and 24 
h were found to have 1 ng/ml KA in their plasma. This study found low penetration of KA into the 
bloodstream; however, no adverse effects were identified (Sansho Seiyaku Co., 2001). 
 
The consumption of fermented food containing undetermined quantities of KA showed blood plasma 
concentrations of 1-8 µg/ml within 12-24 h. This, as well as other studies, indicated that KA was 
absorbed by the gastrointestinal tract (Niwa and Akamatsu, 1991, Higa et al., 2000). According to the 
International Agency for Research on Cancer (IARC), studies into the metabolism of KA have not 
been established. KA's structure allows for a metabolism similar to that of dietary hexoses (Burdock 
et al., 2001). The in vitro metabolism of KA to comenic aldehyde has been carried out in 
Anthrobacter ureafaciens (K-1), a soil-dwelling microorganism that utilises KA as a sole carbon 
source. The proposed enzyme responsible for the degradation of KA was hypothesized to be a non-
heme iron protein-containing ferric ion responsible for accepting hydrogen (H
+
) released from KA 
(Imose et al., 1970). The ferrous ion formed is oxidised by oxygen (aerobic conditions) or 
nicotinamide adenine dinucleotide (NAD) (anaerobic conditions) to produce hydrogen peroxide 




Limited data is available on the absorption, distribution, metabolism, and excretion of KA in humans; 
however, more information is available on the distribution and metabolism of KA in rat models. [
14
C] 
KA was used to dose JCL Wistar rats with 10 µCi/100g via oral, subcutaneous, and dermal routes. 
The study found that KA was rapidly distributed in tissues and organs within 30 mins of 
administering a single oral dose. Additionally, very high levels of KA were found in the liver, kidney, 
and pancreas, while high levels were found in the lung, heart, and spleen. Blood KA levels were 
assessed after 0.5, 1, 3, 6, 24, and 48 h of KA administration. In the blood, a 20.63% and 25.05% 
decrease in administered KA doses was observed at 30 min and 1h, respectively. Assessment of bile 
revealed 0.5 µCi/10µCi of the administered dose within 24 h and no enterohepatic circulation 
occurred. The elimination of KA from the body was assessed in rats following a single oral dose; it 
was found that approximately 70% was in urine, and 0.82% of the administered quantity was excreted 
in faeces within 48 h (Sansho Seiyaku Co., 2001). 
 
Subcutaneous and dermal exposures, showed high levels of KA in the kidney within 30 min and 1h; 
however, there was no significant KA was found in the liver (Sansho Seiyaku Co., 2001, Burnett et 
al., 2010). Blood KA levels were found to be 13.29% and 21.67% of the administered dose within 30 
min and 1 h of subcutaneous exposure and 5% detected through dermal exposure after 30 min. 
Assessment of bile found 0.76 µCi/10 µCi for subcutaneous and dermal exposures, respectively. The 
excreted doses were more significant in urine samples within 48 h measuring 50% and 56% of the 
subcutaneous and dermal administered doses. Expired air was assessed within 5 h and found 1.4% of 
the subcutaneous single administered dose (Sansho Seiyaku Co., 2001). 
 
A repeated dose for subcutaneous exposure in JCL Wistar rats for a period of 7 days was assessed. 
Observation of the relationship between [
14
C] KA and blood and urine samples revealed an increase in 
the concentration of KA detected until equilibrium was reached. The distribution of KA significant in 
organs and tissues, namely the intestinal tract, pancreas, and adipose tissue was assessed at 10 min, 1, 
6, 24, and 48 h. The excreted concentration was assessed in urine and bile. Metabolites such as 
sulphate conjugated to KA (35.6-93.7%) and glucuronides (6.4-39.6%) were detected in urine and bile 
(Sansho Seiyaku Co., 2001). In a review by the Scientific Committee of Consumer Products (SCCP), 
repeated doses of KA showed a significant increase in concentrations distributed and excreted 
compared to a single dose. 
 
The pregnant rats and nursing rats were dosed with 10 µCi/100g to illustrate KA's transfer from 
nursing JCL Wistar rats and pups via milk, amniotic fluid, uterus, and placenta. The pregnant rats 




 day of gestation. Foetuses were examined following 
removal at 10 min, 30 min, and 3 h after treatment. After treatment, very high KA levels were 
observed in the kidney, liver, pancreas, spleen, salivary glands, and lungs. KA levels were detected 
22 
 
within 30 min in the uterus, placenta, amniotic fluid, and foetus. The distribution of treatment in the 
foetus was similar to that of the adults displaying elevated KA levels in the liver and gastrointestinal 
tract. The milk transfer study was dosed on the 3
rd
 day of lactation, and pups were examined at 30 
min, 1 h and 3 h. The pups' stomach wall and contents had 0.02% KA after a 3 h incubation. KA is 
distributed freely to the foetus, uterus, reproductive organs, and secreted milk in JCL Wistar rats 
(Sansho Seiyaku Co., 2001, SCCP, 2008). 
 
Figure 1.2 Proposed metabolism of KA in microorganisms (prepared by author) 
1.2.3. Mechanism of tyrosinase inhibition 
Melanin is produced by the transportation of structural proteins from the endoplasmic reticulum (ER) 
and the fusion of melanosome-specific regulatory glycoproteins. These glycoproteins are released as 
coated vesicles from the Golgi apparatus. They are sorted and transported to the melanosome. 
Melanin is produced in melanocytes and then transferred to keratinocytes hence forming 
pigmentation. Melanogenesis is important for protecting the skin from ultraviolet radiation (UV) 
(Brenner and Hearing, 2008, Zolghadri et al., 2019).  
 
Polyphenol oxidase (tyrosinase) is widely found in plant and animal tissue (Pawelek and Körner, 
1982, Mayer, 1986). It is a metallo-protein enzyme-containing histidine residue that binds copper ion 
at its active site (Gillbro and Olsson, 2011). The enzyme is responsible for the colour of epidermal 
cells such as skin, eyes, and hair of animals (Pekkarinen et al., 1999). Tyrosinase catalyses two steps 
in melanogenesis; the hydroxylation of tyrosine to 3, 4-dihydroxyphenylalanine (L-DOPA) as 




There are two types of melanin in skin, namely pheomelanin and eumelanin. Depending on the type 
of melanin being produced, either dopachrome or cysteinyldopa can be formed. Cysteinyldopa 
produces pheomelanin, whereas dopachrome is used to produce eumelanin with the assistance of 
tyrosinase-related protein 1 (TRP-1) and tyrosinase-related protein 2 (TRP-2).  The melanosomes are 
transferred to keratinocytes by TRP-1 and TRP-2 (Masum et al., 2019). KA has the ability to form 
salts with metals such as sodium, copper, zinc, calcium, nickel, and cadmium (Coupland and Niehaus, 
1987b, Saeedi et al., 2019). KA chelating properties are crucial in the inhibition of tyrosinase activity. 
KA inhibits the process by chelating the copper ion (II) found in tyrosinase hence decreasing melanin 
production (Chen et al., 2013). KA is a slow-binding inhibitor that binds to active tyrosinase present 
(Chang, 2009). KA inhibits melanosis by inhibiting oxygen uptake that aids in browning. The 
competitive inhibition of tyrosinase has led to its use as a preservative in food products and as a skin 
lightening agent in the beauty industry (SCCP, 2008). 
 
Other skin lightening compounds are also tyrosinase inhibitors, such as hydroquinone (HQ). HQ is a 
preferred treatment for hyperpigmentation; however, it has chronic side effects such as nephrotoxicity 
and carcinogenesis (Findlay et al., 1975, Kooyers and Westerhof, 2004). Due to safety concerns, HQ 
is no longer used to treat hyperpigmentation, and KA has become a more popular option due to its 
similar mechanism of action. A study by Azami et al. (2017) evaluated KA's tyrosinase inhibition 
potency by assessing KA's interaction with mushroom tyrosinase binding sites. KA bound to the 
histidine at sites, His263, His259, His296, His94, His85, and His61. It was found that tyrosol and KA 
bind to region 1 of tyrosinase and therefore, compete for binding. KA is a potent inhibitor of 





Figure 1.3 KA inhibits tyrosinase activity in animals and humans. Chemical structures were 
drawn using PubChem Sketcher Version 2.4. 
1.2.4. Effects of KA in vitro and in vivo 
1.2.4.1. Biological effects of KA in vitro 
KA is commonly referred to as an anti-tumour and anti-cancer treatment. A study assessing the 
proliferative nature of KA and its derivatives in HeLa cells found that KA (25 µg) did not induce cell 
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cycle arrest in the absence and presence of 50 µM copper ion (Chen et al., 2013). A proteomic 
assessment of KA [8 µg/ml] (safe recommended concentration) was used to treat A375 cells for 24, 
48, and 72 h. At 72 h, a significant fold-change of 16 differentially expressed proteins responsible for 
apoptosis and cell signalling, namely p53, Ras/mitogen-activated protein kinase kinase (MEK)/ the 
extracellular-regulated kinase (ERK), RAF-1, and B-cell lymphoma 2 (Bcl-2), was observed. KA 
suppressed heat-shock proteins (HSP), which are proteins found to facilitate tumour growth and 
survival (Nawarak et al., 2008), validating KA’s anti-cancer potential.  
 
KA is well-established as a skin lightener due to the inhibition of tyrosinase activity. The inhibition of 
tyrosinase activity has been associated with proliferation due to microphthalmia-associated 
transcription factor (MITF) functions in cell survival and differentiation (Hodgkinson et al., 1993, 
Hughes et al., 1993). KA-induced cytotoxic effects on B16F1 melanoma cells at higher concentrations 
[125- 500 µg/ml] but not at lower concentrations [7.81- 31.25 µg/ml] (Lajis et al., 2012). 
Inflammatory mediators play a role in melanocyte proliferation, differentiation, and pigmentation (Lin 
and Fisher, 2007). KA [0.2 mM] inhibited melanogenesis by stimulating interleukin-6 (IL-6) in 
keratinocyte and melanocyte co-cultures (Choi et al., 2012). 
 
KA’s ability to treat skin conditions was determined on human transfected-HaCaT and SCC-13 cells. 
It was found that 10 mM KA was a potential inhibitor of nuclear factor kappa B (NF-κB) activation in 
human epithelial cells for 24 h (Moon et al., 2001). Many skin-related conditions, such as psoriasis 
and keloids, exhibit elevated inflammatory markers during the condition's development and 
progression. KA [100 µM] was found to be a potential inhibitor of senescence through NF-κB and 
p21 pathways in HCEC cells following treatments at 1, 3, 5, and 7 days (Wei et al., 2019). The p21 
plays a role in the cell cycle, apoptosis, and transcriptional regulation after DNA damage has 
occurred. The p21 protein was found to inhibit caspase 3 and 9 activations, resulting in apoptosis 
prevention (Karimian et al., 2016).  
 
KA is known to be a chemo-sensitising agent of complex III inhibitors in the electron transport chain 
(ETC) (Kim et al., 2013). As a result of the sensitisation of complex III inhibitors, cellular energy 
production may be disrupted, resulting in the escape of electrons leading to reactive oxygen species 
(ROS). A study by Oncul et al. (2019), highlighting the initiation of the intrinsic pathway of apoptosis 
by KA derivatives, found an approximate IC50 of KA > 100 µM. It was also found that KA derivatives 
had increased ROS production in HepG2 cells. Pro-apoptotic factors such as c-Jun-N-terminal kinase 
(JNK) and Bax were not upregulated; however caspase 3 was activated. KA did not produce the same 
effects in HepG2 cells at 100 µM (Oncul et al., 2019). Studies by Niwa and Akamatsu (1991) on 
neutrophils and lymphocytes have shown a reduction in ROS following KA exposure [5 and 20 
µg/ml] in both xanthine oxidase systems and neutrophils.  
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1.2.4.2. In vivo studies 
1.2.4.2.1. Animal Toxicity 
Skin lightening treatments such as HQ have been found to cause DNA adducts and promote 
carcinogenesis. Research into the effect of KA on carcinogenesis in rats measured the DNA adduct 
formation and cell proliferation in hepatocytes. A study by Higa et al. (2007) investigated 
carcinogenic initiation potential in 2% KA orally treated F344 rats for 4 weeks with sodium 
phenobarbital (PB), a carcinogenic promotor, and found no significant increase in pre-neoplastic 
legions shown by biomarker glutathione S-transferase placental (GST-P) positive foci ( > 0.2 mm). 
An increase was observed in a group initiator treatment without promotion treatment (Higa et al., 
2007). The result showed an increase in proliferation but no significant 8-oxodeoxyguanosine levels 
(8-OxodG) in male F344 rats receiving 2% KA doses for periods of 3, 7, and 28 days. F344 rats dosed 
with KA once [0, 1000, 2000 mg/kg body weight] for 2 weeks showed no liver tumour initiating 
capacity, but some data showed that liver tumours may occur. Interestingly, KA did not exert rat liver 
initiation in tumours following a single dose (Watanabe et al., 2005 ); however prolonged dietary 
intake showed increased tumour promotion. Contrary to in vitro studies, in vivo mice studies found no 
data suggesting KA has potential to initiate tumours following liver assessments (Ishikawa et al., 
2006, Moto et al., 2006, Ogiwara et al., 2015). With contrasting results in in vivo and in vitro models 
regarding KA, no conclusive deductions could be obtained. 
 
The genotoxic tumour initiating potential of KA (0, 0.002, 0.02 and 2%) was assessed in rat thyroid at 
various periods (2-31 weeks), and found that oxidative stress was decreased accompanied by the 
absence of DNA-adducts. It was established that there was low to no genotoxicity of KA in the 
thyroid (Tamura et al., 2006). Similarly, Fujimoto et al. (1999) determined KA proliferative effect in 
the thyroid was not influenced by KA genotoxicity.   
 
KA toxicity in terms of lipid peroxidation and iron chelation was assessed in CD-1 mice dosed [100 
mg/kg in 0.25% methylcellulose] for 7 days, and male Wistar rats dosed ad libitum [0.5% KA] in 
water for 4 weeks. Oral doses of 100 mg/kg for 7 days did not affect iron levels accumulated in the 
liver compared to the control (iron chelator- deferoxamine); however, increased lipid peroxidation 
was observed. Oral doses of 0.5% KA for 4 weeks did not have any effect. KA showed minimum 
effect with no protective effect against reperfusion injury (Kotyzova et al., 2004). This result was 
validated in rabbit hearts dosed with 30 µM, displaying no protective function after reperfusion 
illustrated by any improvement in left ventricular function (Katoh et al., 1992).  
 
The teratogenic capabilities of KA are not fully established; however, Choudhary et al. (1992) found 
an increase in mortality and decreased litter size, implantation sites, and viable litters following KA 
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exposure. The study was conducted in Sprague Dawley rats dosed from day 1-5 (female) post-coitum 
with KA (50 µg/day/rat). The rats were laparotomised at day 8, and the corpora luteum comparison 
found no change compared to the control. The study concluded an increase in mortality with no 
teratogenic effects (Choudhary et al., 1992). 
 
A risk assessment of KA in feed due to mycotoxin contamination was assessed in broiler chickens [> 
2 g/kg] between hatchlings and 21-day old chickens. A decrease in growth rates in 21-day old birds as 
well as effects on pro-ventriculus, gizzard, pancreas, and Bursa of the Fabriculus following KA 
treatment [4 - 8 g/kg] was observed (Giroir et al., 1991). Notably, KA was a gastrointestinal irritant 
and inflammatory promotor of the pro-ventriculus and gizzards. Liver toxicity was observed by the 
increase in relative weight and serum glutamic oxaloacetic transaminase (GOT) activity. The Bursa of 
Fabricius' immune activity was altered along with pancreas toxicity. Haematological effect included 
increased red blood cells and decreased mean corpuscular volume. This was hypothesized to be due to 
the stimulation of erythropoiesis and hemoconcentration (Giroir et al., 1991). 
 
Previous studies by Klein and Olsen (1947) stated that low KA concentrations inhibit oxidation 
enzymes in rat livers, namely D-amino acids, L-phenylalanine, and L-methionine. Giroir et al. (1991) 
further proved the altered activity of serum GOT, alkaline phosphatase, and creatine kinase. It was 
established that KA increased total protein, cholesterol, albumin, and triglycerides due to alterations 
in lipid and protein metabolism; however, more research is required to deduce the mechanisms by 
which KA causes these serum concentration changes.  
 
Kidney dysregulation was observed by the increased concentration of uric acid and serum glucose 
concentrations, possibly, due to damage to the Islets of Langerhans in the pancreas. The alteration of 
glucose could explain the decreased colon temperature in the 8 g/kg KA-treated chickens (Giroir et 
al., 1991). Notably, 2 g/kg and above concentrations caused toxicity detrimental to broiler chicken 
health. Contaminated feed was found to contain KA concentrations of 1 to 25 mg/g; however, Wilson 
(1966) found only trace amounts of KA that do not pose a risk to chicken health. 
1.2.4.2.2. Human Toxicity 
KA is commonly used in creams for beauty applications. To determine sensitivity, 107 patients with 
chloasma were treated with KA creams [2.5% KA] twice daily for an average of 9.5 months. Two 
individuals developed facial dermatitis due to hypersensitivity. No sensitivity was detected in 66 
patients with chloasma (Nakayama, 1982) and 31 healthy subjects when treated with the cream [1% 
KA] (Hira et al., 1985). According to studies carried out by Nakayama (1982), no sensitivity was 




In a similar study by Nakagawa et al. (1995), the frequency of sensitisation to KA was assessed in 
patch tests of 220 female patients with suspected cosmetic-related dermatitis. Of the total patients, 8 
used one skin product with KA. Five reacted to KA and one or more products containing 1% KA. 
Three remaining patients showed no reaction to products containing KA. The 212 patients who did 
not use KA previously showed no adverse results (Nakagawa et al., 1995).  
. 
1.3. Cell Death 
Cell death is a process employed by the body to maintain physiological and pathological homeostasis 
during cellular stress. Cell death also allows for the release of chemicals (danger signals) by the dying 
cells to alert the organism or colony of a potential threat (Galluzzi et al., 2018). The process of cell 
death can be categorised into two categories: programmed cell death and accidental cell death. 
However, some overlap of characteristics does exist (Galluzzi et al., 2018). 
1.3.1. Apoptosis (Programmed cell death) 
Apoptosis is a regulated, genetically determined process that occurs when the cell undergoes self-
destruction. The process ensures the elimination of damaged cells that may exhibit protein cross-
linking, protein cleavage, and DNA breakdown (Hengartner, 2000, Elmore, 2007).  
The mechanism of apoptosis is an energy-requiring process that initiates alterations in biochemical 
features of the cell. When apoptosis occurs in a cell, there are characteristic changes such as 
chromatin condensation, nuclear fragmentation, reduction of cellular volume, reduction of 
pseudopods, and the rounding of the cell (Hanahan and Weinberg, 2000). The condensation of 
chromatin occurs at the periphery of the nucleus and can be visualised as a ring structure. The 
chromatin further condenses and breaks up by a process termed karyorrhexis. Throughout this 
process, the cell membrane remains intact. Loss of membrane integrity and membrane blebbing 
occurs at later stages of apoptosis. In normal functioning cells, phagocytic cells engulf apoptotic cells 
as soon as detected.  
Caspases (cysteine aspartic proteases) are proteolytic enzymes that cleave aspartic residues on 
proteins, resulting in apoptosis induction (Shalini et al., 2015). There are ten main categories of 
caspases that are responsible for different specificities. They are categorised into initiators (caspases -
2, -8, -9 and -10), executioners (caspases -3, -6 and -7) and inflammatory caspases (caspases -1, -4 
and -5) (Cohen, 1997). The two main pathways of apoptosis are the extrinsic (death receptor) pathway 
and the intrinsic (mitochondrial) pathway (Fig 1.4). 
1.3.1.1. The intrinsic apoptotic pathway 
The intrinsic pathway is stimulated by external stimuli that include DNA damage, ischemia, and 
oxidative stress. The activation of the intrinsic pathway occurs via the mitochondria and is affected by 
both pro-apoptotic and anti-apoptotic members of the Bcl-2 family. Under stress conditions, the inner 
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mitochondrial membrane (IMM) permeability increases, allowing molecules to enter into the 
mitochondrial matrix leading to the disruption of the oxidative phosphorylation (OxPHOS). Osmotic 
swelling and the compression of vesicles cause unfolding of the inter-cristae space (Redza-Dutordoir 
and Averill-Bates, 2016). An increase in the outer mitochondrial membrane permeabilisation 
(MOMP) results in the release of pro-apoptotic proteins, namely cytochrome C, apoptosis-inducing 
factor (AIF), endonuclease G (endo G), and secondary mitochondria-derived activator of 
caspases/direct inhibitor of apoptosis (IAP)-binding protein with low pI (Smac/Diablo). In the cytosol, 
cytochrome C forms an apoptosome complex with apoptotic protease-activating factor 1 (Apaf-1) and 
procaspase-9 (Redza-Dutordoir and Averill-Bates, 2016). The hydrolysis of adenosine triphosphate 
(ATP) by the apoptosome complex allows for the cleavage of caspase-9, which in turn cleaves 
caspase -3, -6, and -7. The activation of executioner caspases results in apoptosis (Loreto et al., 2014). 
Members of the Bcl-2 family responsible for exerting anti-apoptotic functions are mainly located at 
the outer mitochondrial membrane (OMM). They form heterodimers with pro-apoptotic proteins 
(Bax, Bim, Bak, Bad), thus inhibiting pro-apoptotic signalling (Redza-Dutordoir and Averill-Bates, 
2016)  
1.3.1.2. The Extrinsic apoptotic pathway 
The extrinsic pathway of apoptosis occurs through the transmembrane receptor-mediated interaction. 
These receptors are involved in transmitting death signals from the cell surface to the intracellular 
signalling pathway (Wong, 2011). The death receptors and ligand pairs include FasL/FasR, 
TNFα/TNFR1, Apo3L/DR3, Apo2L/DR4, and Apo2L/DR5 (Elmore, 2007). Binding of ligands to 
respective receptors results in the recruitment of cytoplasmic adaptors; fatty acid synthetase ligand 
(FasL) binding to the fatty acid synthetase receptor (FasR) results in the recruitment of Fas-associated 
death domain (FADD). Tumour necrosis factor-alpha (TNF-α) binds to the tumour necrosis factor 
receptor-1 (TNFR1) resulting in the binding of TNF receptor-associated death domain (TRADD) and 
recruitment of FADD and receptor interacting protein (RIP). FADD dimerizes with procaspase-8 at 
the death effector domain. A death-inducing signalling complex (DISC) is formed, which activates 
pro-caspase 8 (Elmore, 2007). 
 
The execution of apoptosis is the final pathway initiated by the activation of execution caspases -3, -6, 
and -7. These caspases activate cytoplasmic endonucleases and proteases, which degrade nuclear 
material and cytoskeleton and nuclear proteins, respectively (Elmore, 2007). Caspase 3 plays a crucial 
role in the execution pathway by the cleavage of the inhibitor of caspase-activated DNAse (CAD), 
known as ICAD. CAD degrades chromosomal DNA leading to chromatin condensation. Caspase 3 










Necrotic cell death is characterised as the swelling and rupturing of intracellular organelles resulting 
in plasma membrane breakdown. The cell contents, such as cytoplasmic enzymes, are released into 
the extracellular matrix (Chan et al., 2013). The plasma membrane leakage results in the mediation of 
inflammatory responses. Cytokines in the TNF family have been found to trigger necrosis. The 
defining difference between necrosis and apoptosis is plasma membrane lysis before the activation of 
catabolic enzymes in necrotic cell death as opposed to activation of proteases and endonucleases 
before lysis of the cell (Kroemer et al., 1998). A key marker of necrotic death and membrane damage 
is the leakage of lactate dehydrogenase (LDH), found in the cells' cytoplasm (Chan et al., 2013). 
 
1.4. Liver 
1.4.1. Function and hepatotoxicity 
The liver is often affected by toxic insult due to its role as a hub of metabolic activity. The liver uses 
lysosomes for the detoxification of xenobiotics via biotransformation. Liver metabolism converts 
lipophilic compounds into a hydrophilic compound in a two-phase process. Biotransformation occurs 
primarily in the endoplasmic reticulum in hepatocytes. The reactions in phase I are carried out by 
cytochrome P450 (CYP450) enzymes. In phase I, the product undergoes oxidation, reduction, or 
hydrolysis, resulting in an oxygen species' addition. The addition of the oxygen species allows for 
greater reactivity of enzymes with the xenobiotic. Phase II involves the conjugation of glucuronate, 
glutathione, or sulphate to the compound enabling the secretion into blood or bile (Kalra et al., 2020 ).  
Due to the liver's relationship with the gastrointestinal tract and its functions in the detoxification of 
xenobiotics, the liver is prone to toxic insults (Abou Seif, 2016). Injury or impairment of the liver can 
be severe for an individual's health. Hepatotoxicity is dependent on the dose, type of xenobiotic, and 
frequency of exposure (Casas-Grajales and Muriel, 2015). 
1.5. Oxidative stress 
The overproduction of reactive species can cause an electrochemical imbalance resulting in oxidative 
stress. ROS is a term used to refer to metabolic by-products such as superoxide radicals (O2
•−
), H2O2, 
and hydroxyl radicals (•OH) of biological processes (Pizzino et al., 2017). The majority of 
intracellular ROS is produced in the mitochondria (Murphy, 2009); however, the organelle is also a 
target of ROS damage (Ott et al., 2007). Oxidative stress has been associated with diseases due to 
oxidative damage to biomolecules, such as DNA, lipids, and proteins (Liguori et al., 2018).  
1.5.1. Mitochondrial production of reactive oxygen species (ROS) 
The mitochondrion, commonly referred to as the 'powerhouse of the cell', is a double-membrane 
structure that provides energy in the form of ATP for intracellular metabolic processes. The 
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mitochondria also have various roles in nicotinamide adenine dinucleotide phosphate (NADPH) 
synthesis, DNA repair, metabolic pathways, and cell death (Kakkar and Singh, 2007). The ETC 
consists of transmembrane complexes (I-IV), ubiquinone, and cytochrome c, present in the cristae 
(folded inner membrane of mitochondria).  
The mitochondrial ETC complexes may leak electrons to molecular oxygen leading to the production 
of superoxides. Superoxide radicals are produced by NADPH oxidase, xanthine oxidase, and 
peroxidases and non-enzymatic electron transfers to molecular oxygen (Pizzino et al., 2017). 
Superoxide production occurs in the IMM. In the ETC, electrons are transferred by NADH and flavin 
adenine dinucleotide (FADH2) to complex I and II, and electrons are transferred to complex III by 
coenzyme ubiquinone (Zhao et al., 2019). Ubiquinone plays a role in linking complexes I and III, 
complex I and II, and superoxide production by complex III (Fig 1.5) (Ott et al., 2007). The 
superoxide anion is a precursor for most ROS and yields hydrogen peroxide, peroxynitrite, and 





reaction) (Pizzino et al., 2017). 
 
Figure 1.5 Overview of the ETC present in mitochondria and responsible for producing ATP in 
the cell (Zhao et al., 2019) 
1.5.2. Lipid peroxidation 
Lipid peroxidation is a process that involves reactive species oxidising lipids to form aldehydes and 
peroxides. The products formed in lipid peroxidation are more stable than parent reactive species and 
exit the site of generation and inflict tissue damage and dysfunction. The lipid peroxidation products 
are highly reactive and can exert their effects on DNA, protein, and cell signalling (Ramana et al., 
2013). Reactive species attach lipids with carbon-carbon double bonds, especially polyunsaturated 
fatty acids (PUFAs). 
 
Lipid peroxidation is a 3-step process that involves an initiation, propagation, and termination step. 
The initiation step consists of hydrogen abstraction whereby peroxidants abstract allylic hydrogen to 
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form a carbon-centered lipid radical. The propagation step involves the lipid radical reacting with 
oxygen to form lipid peroxy radicals that further abstracts hydrogen from another lipid, thus forming a 
new lipid radical. This initiates a chain reaction between neighbouring lipid molecules. The chain 
reaction continues until a donor antioxidant, such as vitamin E, donates hydrogen to a lipid radical to 
form a nonradical product (Fig. 1.6). This is known as the termination step in lipid peroxidation 
(Ayala et al., 2014). 
 
 
Figure 1.6 The chain reaction that occurs in lipid peroxidation illustrating the key steps i) 
initiation, ii) propagation, and iii) termination (Gaschler and Stockwell, 2017) 
1.5.3. Oxidative DNA damage 
DNA plays a crucial role in transferring genetic information in living organisms. DNA structural 
damage can occur due to endogenous and exogenous factors. A common cause of DNA modifications 
is ROS, while external factors such as ultra-violet radiation can also play a role (Wiesmüller et al., 
2002). The effect of DNA damage, depending on where in the cell the damage occurs, can cause cell 
cycle arrest resulting in cell death. In the event of oxidative DNA damage, modifications of purine 
and pyrimidine bases, deoxyribose backbone, single and double-strand breaks, and cross-links with 
other molecules occur (Ott et al., 2007). DNA modifications have been implicated in premature aging, 
cancer, and neurodegenerative diseases. Mitochondrial DNA (mtDNA) is particularly susceptible to 
damage by ROS potentially due to the absence of a complex chromatin organisation which functions 
as a barrier to ROS, proximity of the OxPHOS, inadequent DNA repair mechanisms in the 
mitochondria and the effect of secondary ROS reactions on mitochondrial membranes due to lipid 
peroxidation (Yakes and Van Houten, 1997, Ott et al., 2007, Singh et al., 2015). 
A common reactant with DNA is the OH
•  
that adds double bonds and abstracts H
+
 from the methyl 
group of thymine and the CH bond at the 2'-deoxyribose. Oxidative DNA damage occurs at the C5, 
C6, and C8 positions, which results in the C5-OH and C6-OH pyrimidine adduct radicals (Cooke et 
al., 2003). The DNA adduct radicals formed is dependent on redox capabilities. A common adduct 










 product. The resultant cation forms a C8-OH, and subsequently, oxidation occurs to 
form DNA modified products (Fig 1.7). An H abstraction between 8-oxoguanine and 2'-deoxyribose 
results in DNA strand breaks (Cooke et al., 2003).  
 
Figure 1.7 The formation of 8-OHdG DNA adduct due to oxidative stress (Valavanidis et al., 
2009) 
1.5.4. ROS-mediated cell signalling  
ROS functions as a secondary messenger to signalling pathways responsible for cell proliferation and 
differentiation. A change in ROS levels initiates the transduction of signalling molecules from the 
plasma membrane to the cell nucleus to exert their functions. ROS interacts with protein kinases, 
protein phosphatases, and transcription factors such as mitogen-activated protein kinase (MAPK) and 
NFκB (Sauer et al., 2001, Zhang et al., 2016). 
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1.6. Response to oxidative stress 
1.6.1. Nuclear factor erythroid-2 factor 2 (Nrf2) pathway 
Antioxidants scavenge free radicals and reduce their reactivity to maintain the balance of oxidants and 
antioxidants (Casas-Grajales and Muriel, 2015). Mammalian cells have defence mechanisms to 
facilitate the intracellular environment's decontamination to return to homeostasis within cells by 
scavenging ROS (Basak et al., 2017). Nrf2 is responsible for the induction of the phase 2 response 
when oxidative stress is detected as a cellular defence mechanism. This process is dependent on the 
dissociation of kelch-like ECH-associated protein-1 (KEAP-1) from Nrf2. Nrf2 has a high affinity for 
KEAP-1 dimers and therefore binds to each other. KEAP-1 is a repressor that contains zinc that is 
bound to a reactive cysteine thiol. Nrf2 release from KEAP-1 requires the phosphorylation of Ser40 
by protein kinase C (PKC) and oxidation of the cysteine thiol groups of KEAP-1 (Basak et al., 2017). 
Free Nrf2 then translocates into the nucleus, where it acts as a transcription factor that activates the 
antioxidant response element (ARE) and initiates the transcription of antioxidant genes such as 
catalase (CAT) and superoxide dismutase (SOD2) (Fig 1.8). CAT neutralises free radicals by reducing 
peroxides to water and oxygen (Zhang et al., 2017). SOD2 converts superoxide into H2O2 and oxygen 







Figure 1.8 Nrf2-KEAP1 pathway illustrating antioxidant regulation in the cell. Nrf2 is 
dissociated from KEAP1 upon oxidation and translocates to the nucleus. While in the nucleus, 
Nrf2 binds to the ARE that facilitates the transcription of genes that play a role in antioxidant 
response (Chen et al., 2014) 
1.7. Immune response 
1.7.1. MAPK pathway  
The MAPK is an intracellular signalling pathway consisting of serine/threonine kinases involved in 
cell differentiation, growth, development, cell cycle, cell survival, and cell death (Junttila et al., 2008). 
The general mechanism of MAPK cascade involves stimuli-induced activation of upstream kinases by 
cell receptors. This leads to sequential action (MAPKKK  MAPKK  MAPK) (Junttila et al., 
2008). MAPK downstream kinase activation occurs at the tripeptide motif, which forms the basis of 
the classification of the ERK, p38, and JNK. The classification of kinases is based on the sequence of 
the tripeptide. JNK and p38 are termed stress-activated protein kinases (SAPK) due to their roles in 
inflammatory and environmental stress responses (Fig 1.9) (Plattner and Bibb, 2012).   
The p38 protein has physiological roles in both the cytoplasm and nucleus. MAPK p38 has shown 
functions in cell cycle progression, chromatin remodelling, mRNA stability, cytoskeleton 
reorganisation, metabolism, and many other cellular processes.  In apoptotic pathways, P38 has been 
implicated in the delayed response to apoptosis by activating p21 and tumour suppressor protein 
(p53), resulting in cell death (Debacq-Chainiaux et al., 2010). The activation of p38 occurs via the 
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dual phosphorylation of Thr-Gly-Tyr by mitogen-activated protein kinase kinase 3 (MKK3) and 
mitogen-activated protein kinase kinase 6 (MKK6). These MKK's are highly selective to p38 and are 
unable to phosphorylate JNK and ERK1/2. P38 has been associated with the regulation of pro-
inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, and cyclooxygenase-2 (COX-2) (Cuenda 
and Rousseau, 2007).  
JNK has a wide array of functions from neuronal and immunological functions to gene expression, 
cell death, and survival pathways (Zeke et al., 2016). Protein kinase mitogen-activated protein kinase 
kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7) activate JNK via dual 
phosphorylation at Tyr and Thr (Weston and Davis, 2002). JNK is responsible for the activation of c-
Jun, which leads to increased expression of activator protein-1 (AP-1). AP-1 (c-Jun & c-Fos) 
regulates cell growth, differentiation, and cytokines transcription (Fisher and Voorhees, 1998, Xie et 








Inflammation is the immune system's response to toxic insult, pathogens, and damaged cells. 
Inflammation is not only a defence mechanism to remove dangerous stimuli and initiate healing, but 
also a consequence of several diseases (Chen et al., 2017). 
1.7.2.1. Sirtuin 1(Sirt1) and inflammatory regulation 
Sirt1 expression has been linked to inflammatory regulation and cytoprotection in different cell lines 
(Xie et al., 2013a).  Sirt1 undergoes phosphorylation by JNK1 and JNK2 at multiple serine and 
threonine residues. JNK and other kinases regulate Sirt1 expression; however, it is unknown which 
regulatory mechanism is involved in Sirt1 alteration of inflammatory responses (Xie et al., 2013a). 
Studies carried out by Alcendor et al. (2007) revealed that Sirt1 regulates ROS levels by elevating 
CAT expression. The increase in CAT expression was induced by forkhead box protein O1 (FoxO1); 
Sirt1 deacetylates FoxO1, FoxO3a, and FoxO4, which in turn, activates antioxidants such as CAT, 
SOD2, and thioredoxin (Trx) (Salminen et al., 2013). Nevertheless, upregulation of Sirt1 also caused 
oxidative stress by deacetylating the Lys588 and Lys591 residues of Nrf2 and repressing its 
antioxidant function (Kawai et al., 2011).  Sirt1 is also responsible for the regulation of ROS by 
controlling immune responses via NFκB. Sirt1 inhibits the activation of NFκB by the deacetylation of 
Lys310 residues found on RelA/p65 (Fig 1.8) (Yeung et al., 2004). Furthermore, Sirt1 expression has 
been associated with the deacetylation of transcription factors of AP-1 (Xie et al., 2013a).  
1.7.2.2. Nuclear factor-kappa β (NFκB)  
NF-κB is a transcription factor responsible for the induction of an immune response and 
inflammation. NFκB is induced in response to stimuli from the environment. NFκB, when 
unstimulated in cells, can form a complex with IκB (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha), an inhibitory protein. Activator molecules such as TNF-α, 
interleukin 1 (IL-1β), lipopolysaccharide (LPS), and UV radiation can lead to the phosphorylation of 
NF-κB and the degradation of IκBα. The activated NF-κB translocates to the nucleus and alters the 
expression of target genes (Ahn et al., 2003). Chelators of iron and copper were found to inhibit the 
activation of NF-κB (Schmilz, 1995). Exposure to TNF-α, IκBα can become phosphorylated by IκB 
kinases (IKK). IKK comprises of IKKα and IKKβ (Chen et al., 2017). This may result in the 
ubiquitination or degradation of the freed NFκB. The NFκB transcription genes' repression or 
activation is responsible for mediating inflammatory and immune responses by Th2 cytokines, 
chemokines, COX-2, matrix metallopeptidases (MMP’s), and apoptotic factors (Fig 1.10) (Messadi et 




Figure 1.10 Overview of the NFκB pathway activation. Stimuli, such as ROS, can induce the 
activation of NFκB and degradation IKβ. NFκB translocates to the nucleus and transcribes for 
inflammatory and immune responses. MAPK regulates NFκB and AP-1 via Sirt 1 expression 
(prepared by author). 
1.8. MicroRNAs (miRNAs) 
MiRNAs are small, non-coding RNAs that interact with the 3’ untranslated region (UTR) region of 
mRNA for the post-transcriptional regulation of gene expression. However, some miRNAs may 
interact with the 5' UTR region, gene promoters, and coding sequences (O'Brien et al., 2018). The 
formation of mRNA-miRNA complex results in translational repression or mRNA degradation (Fig 
1.11) (Maurer et al., 2010). MiRNAs are involved in biological processes, including proliferation, 
apoptosis, and differentiation (Maurer et al., 2010). MiRNAs have been found to regulate 
approximately 30% of the human genome. The dysregulation of miRNAs has been associated with 
cancer, neurological, cardiovascular, and autoimmune diseases (Wiemer, 2007, Lukiw et al., 2008, 




Figure 1.11 MiRNA function in mRNA degradation and translational repression (prepared by 
author) 
1.8.1. MiRNA biogenesis 
MiRNA biogenesis is classified into two pathways namely the canonical pathway and non-canonical 
pathway. MiRNA is generated predominantly from the canonical pathway. 
1.8.1.1. Canonical miRNA biogenesis pathway 
This pathway involves the transcription of primary miRNA (pri-miRNA) from their genes into 
precursor miRNA (pre-miRNA). The canonical pathway is dependent on the microprocessor complex 
which consists of the nuclease III enzyme, Drosha and an RNA binding protein, DiGeorge Syndrome 
Critical Region 8 (DGCR8) (O'Brien et al., 2018). DGCR8 recognises motifs within the pri-miRNA 
such as N6-methyladenylated GGAC. Drosha is responsible for the cleavage at the base of the hairpin 
structure of the pri-miRNA duplex. The resultant pre-miRNA is exported to the cytoplasm by an 
exportin 5 (XP05)/RanGTP complex. The pre-miRNA is processed by RNase III endonuclease Dicer 
by removing the terminal loop producing a mature miRNA. The miRNA is assigned a name based on 
its directionality (O'Brien et al., 2018). The miRNA hairpin comprises of a 5p strand arising from the 
5’ region and the 3p strand arises from the 3’ region end. The mature duplex comprising of both 3p 
and 5p can be loaded into the Argonaute (AGO) family of proteins and the process is ATP dependent. 
The amount of AGO-loaded 3p and 5p is dependent on the cell type, cellular environment and 
thermodynamic stability. Strands with lower 5’ stability or a uracil at the 5’ region is preferential and 
is AGO loaded and serves as a guide strand while the unloaded strand (passenger strand) unwinds 
through various mechanisms (O'Brien et al., 2018). 
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1.8.1.2. Non-canonical miRNA biogenesis pathway 
This pathway involves Drosha, Dicer, exportin 5 and AGO2. Non-canonical pathway differs from the 
canonical pathway due to Drosha/DGCR8 and Dicer independent pathways. Pre-miRNA’s are 
produced by Drosha/DGR8 independent pathways resembling Dicer substrates. Mirtrons (pre-
miRNA’s produced from introns of miRNA splicing) and 7-methylguanosine-capped-premiRNA’s 
(m
7
G) are examples of premiRNA’s (O'Brien et al., 2018). The RNA’s are exported to the cytoplasm 
by exportin 1 independent of Drosha cleavage. There is a 3p bias which prevents the 5p strand loading 
on AGO. Alternately, Dicer independent miRNA’s are processed by Drosha and require AGO2 due 
their insufficient length which excludes them as a Dicer substrate. The entire miRNA is loaded into 
AGO2 and the maturation process is completed by 3’-5’ trimming of the 5p strand (O'Brien et al., 
2018). 
1.8.2. MiRNAs role in immune responses 
1.8.2.1. MiRNA-29a 
Studies have shown apoptosis regulation by the downregulation of pro-apoptotic proteins, namely 
Bax, PARP, phospho-FADD, cleaved caspase 8, and caspase 3. It was also determined that miRNA-
29a repressed the expression of NFκB and, in this manner, protects cells from injury and apoptosis 
(Tiao et al., 2014).  
1.8.2.2. MiRNA-29b 
Study carried out by Luna et al. (2009), showed the regulation of extracellular matrix (ECM) genes 
following oxidative stress in HTM (human trabecular meshwork) cells suggesting miRNA-29b is a 
common oxidative stress-modulated miRNA. Moreover, miRNA-29b regulates oxidative stress by 
negatively regulating Sirt1 expression in ovarian cancer cells (Hou et al., 2017). MiRNA-29b 
expression initiated apoptosis by downregulating Bax mRNA expression in cardiomyocytes (Jing et 
al., 2018). Therefore, miRNA-29b plays a role in oxidative stress responses via sirt1 and apoptosis. 
1.8.2.3. MiRNA-155 
Studies have shown miRNA-155 as a potential target for cancer treatment due to the ubiquitous 
oncogene characteristics and promotion of proliferation in human cancer. Of importance was the 
elevated proliferation rate of hepatocellular carcinoma (HCC) when miRNA-155 expression was 
upregulated (Gao et al., 2015). Furthermore, miRNA-155 upregulated MAPK signalling and NFκB 
expression in pancreatic cancer cells leading to increased proliferation and ROS production. 
1.9. Problem statement, aims, and objectives 
1.9.1. Problem statement 
Due to KA’s extensive use in the beauty industry and as a food preservative, the effects on organs 
involved in metabolism of KA such as the liver are potential targets.  In vitro and in vivo studies have 
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demonstrated KA's effect in multi-organ systems; however, the liver is often neglected. The liver is 
the main organ responsible for the detoxification of toxins and thus  susceptible to damage; therefore, 
it is important to assess KA's toxicity in liver cells. To date, research on the effects of KA in liver 
cells cells remains limited. Understanding the potential effects of KA may provide insight on the 
concentrations posing minimal risk (Fig 1.12). 
1.9.2. Alternate Hypothesis 
It was hypothesized that KA induced oxidative stress, inflammation, and activated the MAPK 
signalling pathway in HepG2 cells following 24 h exposure 
1.9.3. Aim 
The study aims to determine the effects of KA on oxidative stress and subsequent alteration on 
immune responses related to NFκB inflammation and MAPK signalling in a human liver (HepG2) 
cell line. 
1.9.4. Objectives 
The effects of KA on HepG2 cells was determined by measuring:  
 mitochondrial output (MTT assay) and ATP luminometry  
  apoptosis using caspase luminometry 
 oxidative stress 
- Lipid peroxidation (TBARS) assay  
- DNA integrity using 8-OHdG ELISA 
- Protein integrity using Protein carbonyl assay 
 MAPK signalling and NFκB inflammatory responses using 
- Western blots of p38, JNK, Nrf2, phosphorylated-Nrf2 (ser40), CAT, phosphorylated-
NFκB (ser536), NFκB, phosphorylated-Sirt1 (ser47) and AP-1  




Figure 1.12 The experimental approach employed to investigate the toxicity of KA in HepG2 
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METHODS AND MATERIALS 
2.1. Materials 
HepG2 cells (HB-8065) were purchased from the American Type Culture Collection (ATCC; 
Johannesburg, South Africa).  Cell culture reagents were purchased from Whitehead Scientific 
(Johannesburg, South Africa). Luminometry kits were purchased from Promega (Madison, WI, USA). 
Western Blot reagents were purchased from Bio-Rad (Hercules, CA, USA). All other reagents and 
consumables were purchased from Merck (Darmstadt, Germany) unless otherwise stated. 
2.2. Cell culture 
2.2.1. Introduction 
The HepG2 cell line is derived from the liver tissue of a 15-year-old Caucasian male with 
differentiated hepatocellular carcinoma (Donato et al., 2015b). HepG2 cells are commonly used for 
drug metabolism and hepatotoxicity studies. Favourable characteristics include an unlimited life span, 
stable phenotype, readily available, and easy to handle. HepG2 cells have an epithelial-like 
appearance and have a high proliferation rate with the ability to perform differentiated hepatic 
functions (Donato et al., 2015a). Due to the wide use of the cell line, extensive research into the 
functional characteristics of HepG2 has been carried out. Although a cancer cell line, HepG2 cells 
have retained characteristics of differentiated hepatocytes such as lipoprotein secretion, albumin 
secretion, glycogen synthesis and glutathione detoxification (Kammerer and Küpper, 2018). HepG2 is 
extensively used in toxicity studies due to the presence of biotransformation enzymes such as Phase I 
(cytochrome P450 monooxygenase) and Phase II (glucuronic and sulphate conjugation), which play a 
role in detoxification (Dehn et al., 2004). 
2.2.2. Protocol 
HepG2 cells were cultured (37ºC, 5% CO2) in 25 cm
3
 cell culture flasks containing Eagle's Minimum 
Essentials Medium (EMEM) supplemented with 10% foetal calf serum (FCS), 1% penicillin-
streptomycin-fungizone, and 1% L-glutamine. FCS provides essential albumin and growth factors 
required for cell attachment, growth, and proliferation (Gstraunthaler et al., 2013). Penicillin-
streptomycin-fungizone is a combination of antibiotics and fungicides that are used to prevent 
bacterial and fungal contamination. Glutamine is an essential amino acid required as a building block 
for proteins involved in cell growth and physiological functions (Cruzat et al., 2018). 
 
The trypan blue cell exclusion technique is used to determine viable cells in cell culture. The cells are 
incubated with trypan blue dye and visualised using a light microscope. The trypan blue cell exclusion 
technique is based principle in which viable cells with intact, selectively permeable cell membranes 
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exclude the dye, whereas damaged cells take up the blue dye (Strober, 2015). This method was used 
to enumerate cells and determine cell viability prior to conducting each assay (Fig 2.1). 
 
Figure 2.1 Trypan exclusion method used for the enumeration of viable cells (prepared by 
author) 
2.3. KA preparation and treatment 
A stock solution of KA (20 mg/ml) was prepared in 0.1 M Phosphate buffered saline (PBS). The cells 
were allowed to reach 80% confluency before incubation with KA [4.22, 8.02, or 12.67 mM]. All 
experiments were performed 3 independent times and in triplicate. 
 
2.4. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
2.4.1. Introduction 
The MTT assay is one of the most commonly used assays to assess the anti-proliferative properties of 
compounds in cells. The assay utilises tetrazolium salts to assess the cell's mitochondrial metabolic 
activity. Mitochondrial metabolic activity is indirectly proportional to cell viability. The tetrazolium 
salts are reduced to insoluble purple formazan crystals by mitochondrial dehydrogenases (Fig 2.2). 
Once the crystals are solubilised with Dimethyl sulfoxide (DMSO), the spectrophotometric reading at 
570 nm is used to evaluate cell viability using the following equation: 
 
% 𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒






Figure 2.2 The reaction catalysed by mitochondrial reductase to produce formazan products 
(Karumuri, 2013) 
2.4.2. Exposure protocol 
HepG2 cells (15,000 cells/well) were seeded in a 96-well microtiter plate and allowed to adhere 
overnight before incubation (37°C, 5% CO2,) for 6, 24 and 48 h with various concentrations of KA (0-
12.67 mM). MTT salt solution [20 µl; 5 mg/ml in 0.1 M PBS] and CCM (100 µl) was added to the 
cells and incubated (37ºC, 4 h). Following incubation, the MTT salt was removed, and DMSO 
(100µl/well) was added to solubilise the formazan crystals. The plate was incubated (37º C, 1 h), and 
the absorbance was measured using a microplate reader (Biotek µQuant Plate reader, Winooski, VT, 
USA) at a wavelength of 570 nm with a reference wavelength of 690 nm. Analysis of the absorbance 
obtained was performed using GraphPad Prism V5.0, and the half-maximum inhibitory concentration 
(IC50) was obtained. 
 
2.5. Crystal violet assay 
2.5.1. Introduction 
The crystal violet assay measures cell viability by assessing the ability of cells to adhere to the cell 
culture vessel. It is based on the principle in which dead cells lose their ability to adhere to cell culture 
surfaces and are lost from the viable population. The crystal violet dye binds to DNA and proteins in 
cells (Fig 2.3). When dead cells detach, the number of cells stained with crystal violet staining 
decreases along with the intensity of the purple colour. The intensity of the purple colour is measured 
spectrophotometrically and describes the cell survival and growth inhibition potential of the treatment 
(Feoktistova et al., 2016). 
2.5.2. Protocol 
Crystal violet assay was performed as per (Feoktistova et al., 2016). HepG2 cells (15,000 cells/well) 
were adhered to a 96-well microtiter plate and incubated (37°C, 5% CO2, 24 h) with varying 
concentrations of KA (0 - 12.67 mM). Following incubation, the cells were washed in dH2O, and 
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0.5% crystal violet stain (50 µl) was added. The plates were incubated for 20 min on a bench shaker at 
20 oscillations per minute. The cells were washed 4 times in dH2O and air-dried overnight at RT. 
Methanol (200 µl) was added to each well, and the plate was incubated at RT for 20 min. The 
absorbance was read in a microplate reader (Biotek µQuant Plate reader, Winooski, VT, USA) at a 
wavelength of 570 nm. Cell viability was determined relative to the control. 
 
 




2.6. Caspase activity 
2.6.1. Introduction 
Apoptosis and necrosis are both types of cell death associated with normal and disease states. The 
Caspase Glo®-3/7, Caspase Glo®-8, and Caspase Glo®-9 assay kits (Promega, Wisconsin, US) were 
used to measure the activities of caspase 3/7, caspase 8, and caspase 9, respectively. The assay kit 
contains aminoluciferin substrates which undergo cleavage by caspases. The freed aminoluciferin is 
catalysed by luciferase to produce luminescent signal. Luminescence is directly proportional to 
caspase activity. 
2.6.2. Protocol 
Luminometry was used to determine KA's effect on caspase-3/7, -8, and -9 activities in HepG2 cells. 
Following treatment with KA for 24 h, HepG2 cells (20,000 cells/well) were seeded in an opaque 96-
well microtiter plate with 25 µl of Caspase Glo®-3/7, Caspase Glo®-8, and Caspase Glo®-9 reagents. 
The plate was incubated for 30 min at RT in the dark and luminescence was measured on a 
Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, USA). The results were 
expressed as relative light units (RLU). 
 
2.7. LDH assay 
2.7.1. Introduction 
Necrosis of cells displays plasma membrane permeation causing the leakage of intracellular contents 
into the extracellular matrix (Chan et al., 2013). LDH is an enzyme that plays a role in the glycolytic 
pathway (Jialal and Sokoll, 2015). The amount of LDH released into the extracellular matrix is 
correlated with the extent of disruption to the cell membrane (Chan et al., 2013). 
LDH catalyses the oxidation of lactate to pyruvate and produces reduced nicotinamide adenine 
dinucleotide (NADH). Tetrazolium salts are converted into a formazan product using the NADH 
product in the presence of an electron acceptor (Chan et al., 2013) (Fig 2.4). The spectroscopic 
reading at 500nm is directly proportional to LDH levels and is used to determine cell membrane 












The LDH cytotoxicity detection kit (Roche, Mannheim, Germany) was used to determine KA's effect 
on cell membrane integrity. Following the treatment of HepG2 cells with KA for 24 h, supernatants 
(100 µl) were transferred into a 96-well microtiter plate in triplicate.  Thereafter, 100 µl INT/sodium 
lactate dye solution and diaphorase/NAD
+
 catalyst were added to each well, and the plate  incubated 
in the dark for 20 min at RT. Optical density was measured on a spectrophotometer (Biotek µQuant 
Plate reader, Winooski, VT, USA) at 500 nm. Results were expressed as the concentration of KA 
(mM) versus optical density.  
2.8. ATP Quantification assay 
2.8.1. Introduction 
The mitochondria produce ATP by the tricarboxylic acid cycle (TCA) enzymes, electron transport 
chain complexes, and ATP synthase (Zhang et al., 2018). ATP is required for several processes such 
as intracellular signalling, DNA and RNA synthesis, and active transport. Therefore, ATP synthesis is 
essential to support cell survival. 
The assay uses bioluminescence to measure the ATP concentration in the cell. A key reaction is the 
luciferase reaction that converts mono-oxygenated luciferin to oxy-luciferin. The reaction requires 
Mg
+
, oxygen, and ATP and results in the release of energy in the form of luminescence (Fig 2.5). The 




Figure 2.5 The principle reaction of the ATP Cell Titre Glo® assay used to quantify ATP 
concentration (prepared by author) 
2.8.2. Protocol  
ATP levels were quantified using the ATP Cell Titre Glo® luminometry assay kit, as previously 
described (Abdul et al., 2016). HepG2 cells (20,000 cells/well) were seeded in an opaque 96-well 
microtiter plate and incubated (RT in the dark, 30 min) with 20 µl of ATP Cell Titre Glo® reagent 
(Promega, Madison, USA). Following incubation, luminescence was measured using the Modulus™ 
microplate luminometer (Turner Biosystems, Sunnyvale, USA). Luminescence is proportional to the 
ATP levels and was expressed as relative light units (RLU). 
 
2.9. Lipid peroxidation (TBARS) assay 
2.9.1. Introduction  
Lipid peroxidation is initiated by hydrogen abstraction from PUFA's due to the presence of excess 
ROS. A lipid peroxidation chain reaction occurs by the initiation of a three-step mechanism involving 
an initiation step, a propagation step, and lastly, a termination step (Ayala et al., 2014). The chain 
reaction produces malondialdehyde (MDA) and 4-Hydroxy-4-nonenal (4-HNE). MDA is used as a 
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biomarker for lipid peroxidation of omega-3 and -6 fatty acids due to its observed reaction with 
thiobarbituric acid (TBA) (Ayala et al., 2014). Thiobarbituric acid reactive substances (TBARS) assay 
is based on the reaction of 2-thiobarbituric acid and one molecule of MDA yielding the chromophoric 
product MDA-TBA adducts measured at 532 nm (Fig 2.6). The reaction occurs at high temperature 
and a low pH. 
 
Figure 2.6 Principle reaction in the lipid peroxidation (TBARS) assay, adapted from Antolovich 
et al. (2002). 
2.9.2. Protocol 
Briefly, 200 µl of supernatants were added to test tubes along with 2% H3PO4 (200 µl), 7% H3PO4 
(200 µl), and 0.1 M TBA/BHT solution (400 µl). A negative control consisting of 3 mM HCl (400 µl) 
and a positive control consisting of 1% MDA (1µl) was also prepared. All samples were vortexed, and 
1 M HCl (200 µl)  added to adjust the pH to 1.5. Samples were heated (100°C, 15 min) and allowed to 
cool to RT before adding butanol (1500 µl). The samples were vortexed (30 s) and allowed to settle 
into two distinct phases.  The upper butanol phase (100 µl) was transferred into a 96-well microtiter 
plate in triplicate, and the absorbance was measured using the Biotek µQuant spectrophotometer 
(Winooski, VT, USA) at a wavelength 532 nm with a reference wavelength of 600 nm. The results 
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2.10. Protein isolation 
2.10.1. Introduction 
Crude protein was isolated from HepG2 cells using 200 µl Cell Lysis solution (50 mmol/l HEPES, 
1% Triton ×100, 10% glycerol, and 50 mmol/l NaCl) for the protein carbonyl assay and 200 µl 
Cytobuster™ reagent (Novagen, USA) supplemented with protease and phosphatase inhibitors for 
Western Blot. Cytobuster reagent is a non-ionic detergent that disrupts cell membranes to yield 
functionally active and expressed proteins when coupled with mechanical scraping.  It is 
supplemented with protease and phosphatase inhibitors to preserve protein integrity (Eslami and 
Lujan, 2010). The process was carried out on ice to prevent protein degradation. 
2.10.2. Protocol 
HepG2 was treated with KA for 24 h. The supernatant was removed from flasks, and adhered cells 
were washed three times with 0.1 M PBS. Isolation of proteins from control and KA-treated HepG2 
cells was carried out using the respective lysis solutions (200 µl). Samples were incubated for 30 min 
on ice before mechanically lysed. The supernatant obtained from the disrupted cells were decanted 
into 1.5 ml micro-centrifuge tubes. The samples were centrifuged at 13, 000 g for 10 min at 4ºC. 
Supernatant containing crude protein was decanted into 1.5 ml micro-centrifuge tubes and kept on ice 
for further quantification and standardization procedures. The pellet was discarded.  
2.10.3. Quantification and standardisation of proteins 
2.10.3.1. Introduction 
The bicinchoninic acid (BCA) assay is used to quantify total crude protein. The method principle 
reaction is the Biuret reaction. BCA is a water-soluble compound that forms an intense purple 
complex with cuprous ions (Cu
+
) in an alkaline environment (Fig 2.7) (Walker, 1996).  The stable 
chromophore BCA-Cu
2+
 complex absorbs light at a 562 nm wavelength (Walker, 1996). The intensity 




Figure 2.7 The principle reactions in the BCA assay used to quantify protein (prepared by 
author) 
2.10.3.2. Protocol 
Bovine serum albumin (BSA) [0, 0.2, 0.4, 0.6, 0.8, and 1 mg/ml], a protein standard, was serially 
diluted using distilled water and used to construct a standard curve. In a 96-well plate, 25 µl of each 
standard (triplicate) and protein sample (duplicate) were added into appropriately labelled wells. A 
working solution (200 µl) containing BCA (198 μl) and CuSO4 (4 μl) was added to each well. The 
plate was incubated at (37°C, 30 min), to allow the reaction between sample protein and Cu
+
 to occur. 
The absorbance was measured at 562 nm using a spectrophotometer (Bio-tek μQuant Plate Reader). 
The standard curve was used to determine the concentration of sample proteins (mg/ml) present by 
extrapolation. The proteins were subsequently standardised to 1 mg/ml for the protein carbonyl assay 
and 1.5 mg/ml for Western blot.  
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2.11. Protein oxidation (Protein carbonyl) assay 
2.11.1. Introduction 
Protein carbonylation occurs when ROS attack side chains of proline, arginine, lysine, and threonine 




) (Celi and Gabai, 2015). The superoxide radicals’ 
mechanism of protein damage involves the oxidation and inactivation of iron-sulphur (Fe-S) proteins. 
Superoxide radicals target proteins such as complex I NADPH dehydrogenase and succinate 
dehydrogenase. The Fenton or Haber-Weiss reaction generates hydroxyl radicals and releases Fe
2+ 
and 
H2O2.   
Primary protein carbonylation is the formation of reactive aldehydes and ketones that can react with 2, 
4-dinitrophenylhydrazine (DNPH). Protein oxidation was quantified by measuring the intracellular 
protein carbonyl groups in the sample at a wavelength of 370 nm. 
2.11.2. Protocol 
The standardised protein (200 µl) was added to DNPH (800 µl) at RT for 1 h. A blank consisting of 
the standardised protein (200 µl) and 2.5 M HCl (800 µl) was also prepared. The solution was 
vortexed after every 15 min interval of the 1h incubation. Following incubation, the protein in each 
sample was precipitated with 20% Trichloroacetic acid (TCA) (1 ml) on ice and vortexed, followed 
by centrifugation (2000 g, 10 min, RT). The pellet formed in each sample was washed twice with 1 ml 
ethanol-ethyl acetate (1:1) and dissolved in 6 mol/l guanidine hydrochloride (500 µl). The samples 
were incubated (37ºC, 10 min) and centrifuged (2,000 g, 10 min, RT) to remove any insoluble 
material. The supernatant (100 µl) was added in triplicate into a 96-well microtiter plate (100 µl) and 
the absorbance was measured at 370 nm with a spectrophotometer. The corrected absorbance was 
calculated by subtracting the average absorbance obtained from the blank from the sample 
absorbance. The protein carbonyl concentration was obtained by dividing the corrected absorbance 




). The results 
were expressed in nanomoles per milligram units. 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑎𝑟𝑏𝑜𝑛𝑦𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙/𝑚𝑙) =
𝑝𝑎𝑡ℎ𝑤𝑎𝑦 (1𝑐𝑚) × 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝐷𝑁𝑃 
 
2.12. Western Blotting 
2.12.1. Introduction 
Western blot is a molecular-based technique used to identify proteins of interest from a heterogeneous 
mixture of proteins in the cell. The technique uses sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) to separate proteins based on their molecular weights (Mahmood and 
Yang, 2012). The charge of the proteins is exploited to ensure the movement of proteins occurs. The 
negative charge of the protein migrates towards the positive electrode through the polyacrylamide gel. 
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The protein's size determines the movement through the gel; the large molecular weight proteins 
migrate slower through the matrix whereas the smaller molecular weight proteins migrate faster 
(Mahmood and Yang, 2012). The protein is transferred onto a solid support such as a nitrocellulose or 
polyvinylidene difluoride (PVDF) membrane. A blocking solution is used to prevent non-specific 
binding of proteins. The membrane is incubated with antibodies specific to the proteins of interest. 
The technique used both primary and enzyme-conjugated secondary antibodies to ensure specificity. 
The membrane is washed and visualised by the reaction between the enzyme conjugated secondary 
antibody and substrate solution. The protein relative band's density (RBD) is proportional to the 
amount of protein present (Fig 2.8) (Mahmood and Yang, 2012). 
 
Figure 2.8 Overview of Western blot procedure (prepared by author) 
2.12.2. Quantification and standardisation of proteins 
2.12.2.1. Protocol 
Laemmli buffer (50 µl; dH2O, 0.5 M Tris-HCl (6.8), bromophenol blue, β- mercaptoethanol, glycerol, 
and 10% SDS) was added to the standardized protein samples for Western blot and boiled (100ºC) for 
5 min. The proteins were allowed to cool at room temperature (RT) and stored at -20°C until the 
western blot procedure was carried out. The buffer solution components serve specific functions 
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required for an efficient gel electrophoresis assay. Tris-HCl is required for the pH buffering of the 
sample solution (Mishra et al., 2017, Bass et al., 2017). Bromophenol blue is a dye used to allow for 
the visualisation of the protein sample as migration through the gel occurs. β-mercaptoethanol acts as 
a reducing agent and denatures protein by breaking disulphide bonds, causing the unfolding of 
proteins (Mahmood and Yang, 2012). Glycerol adds weight to the samples allowing it to sink into the 
gel wells. SDS has a negative charge and alters the charge of proteins, therefore neutralising their 




Polyacrylamide is made up of cross-linker N, N'-methylene bis-acrylamide, and acrylamide, which is 
catalysed by ammonium persulfate (APS). SDS-PAGE comprises of two polyacrylamide gels of 
differing characteristics: a stacking gel and a resolving gel. The stacking gel is acidic (pH 6.8) and has 
larger pores due to a lower acrylamide concentration (Mahmood and Yang, 2012). The gel separates 
proteins poorly and forms thin sharp bands. The resolving gel is basic (pH 8.8) and has narrow pores 
to separate proteins. The proteins are separated by size, and smaller proteins move more rapidly 
through the narrower pores, thus migrating further in the polyacrylamide gel towards the positive 
electrode (Mahmood and Yang, 2012). 
2.12.3.2. Protocol 
Polyacrylamide gels were prepared, and MINI-PROTEAN 3 SDS-PAGE apparatus (Bio-Rad) were 
set up according to the manufacturers' guidelines. A 10% resolving gel [Bis-acrylamide, dH2O, 1.5 M 
Tris (pH 8.8), 10% SDS, 10% APS, and TEMED] was prepared and allowed to set (RT, 1 h). Once 
set, the 4% stacking gel [Bis-acrylamide, dH2O. 0.5 M Tris (pH 6.8), 10% SDS, 10% APS, and 
TEMED] was added above the resolving gel. A 1cm plastic comb was placed in the stacking gel to 
form wells to allow for the loading of samples. The gel was allowed to set (RT, 1 h). 
The prepared gels was placed into the electrode tank, and the electrode was assembled (mini-
PROTEAN Tetra Cell System, Bio-Rad), as per manufacturers guidelines. The samples (25 µl) and 
molecular weight markers (5 µl) were loaded into the wells of the gel . Once loaded, the electrode 
tank was filled with running buffer [25 mM Tris, 192 mM glycine, and 0.1% SDS]. The gel was 




Figure 2.9 Denaturation and alteration of charge of the tertiary structure of proteins by SDS 
and β-mercaptoethanol (prepared by author) 
2.12.4. Protein Transfer (Electro-blotting) 
Following electrophoresis, the gel is prepared before transfer onto the nitrocellulose membrane. The 
stacking gel is removed, and the resolving gel is placed into a gel sandwich assembly.  The gel 
sandwich comprises of two fibre pads, a nitrocellulose membrane, electrophoresed gel, and transfer 
buffer adjusted to pH 8.3 [25 mM Tris, 192 mM glycine, 20% methanol]. The gel sandwich is 
assembled between two electrodes, and the separated proteins are transferred to the nitrocellulose 
membrane using a Bio-Rad Trans-Blot Turbo Transfer System (20 V, 30 min). The protein transfer 
principle depends on the application of an electric charge that is perpendicular to the surface of the 
gel.  The electric current causes the negatively charged proteins to migrate towards the positively 
charged electrode resulting in the proteins being embedded onto the nitrocellulose membrane. 
2.12.5. Blocking and antibody incubation (Immuno-blotting) 
Once the proteins are transferred onto the nitrocellulose membrane, the membrane is incubated in a 
blocking solution to prevent proteins' non-specific binding. The blocking solution comprises of 5% 
BSA or 5% non-fat dry milk (NFDM) in Tris buffer saline with 0.05% TWEEN 20 [TTBS, dH2O, 
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0.05% TWEEN, 150 mM NaCl, 3 mM KCl, 25 mM Tris, pH 7.5]. Membranes are incubated in the 
blocking solution with gentle rotation for 1 h at RT. Primary antibodies (Table 1) were used to 
immunoblot the membranes at RT for 1 h on a shaker. The membranes were then incubated overnight 
to allow for the binding of primary antibodies to specific proteins. Following incubation, membranes 
were equilibrated at RT and washed with TTBS at 10 min intervals between washes to remove 
unbound primary antibodies. The membranes were then incubated in secondary antibodies conjugated 
with horseradish peroxidase [goat anti-rabbit (Cell Signaling Technology, 7074S) and goat anti-
mouse (Cell Signaling Technology, 7076P2) with gentle agitation (1:1,000, 2 h, RT) (Fig 2.12). The 
secondary antibody facilitates the detection of a specific protein by binding to the primary antibody. 
Following the incubation, membranes are washed with TTBS five times at 10 min intervals to remove 
unbound secondary antibodies. 
Table 1. Primary antibody dilutions used in Western blot 
Antibody Catalogue number Dilutions 




AP-1 A5968 (Sigma Aldrich) 
Rabbit polyclonal 
1:5,000 








JNK SAB 4200176 (Sigma Aldrich) 
Mouse monoclonal 
1:5,000 
P38 M8177 (Sigma-Aldrich) 
Rabbit polyclonal 
1:5,000 




Phosphorylated Nrf-2 AB76026 ( Abcam) 
Rabbit polyclonal 
1:5,000 




Protein bands were visualised using the Bio-Rad Clarity Western ECL Substrate Kit and the 
ChemiDoc™ XRS + System. The principle reaction that allows visualisation of proteins occurs 
between the HRP-conjugated secondary antibody and H2O2 to free oxygen radicals. The oxygen 
radicals react with luminol to form aminophtalic acid causing luminescence and enabling the 
visualisation of protein bands.  
 
2.12.7. Quenching and normalisation 
Membranes were quenched in 5% hydrogen peroxide (30  min, 37ºC) and washed once with TTBS 
(10 min, RT). Membranes were blocked with 5% BSA and incubated in HRP-conjugated antibody for 
β-actin (Sigma-Aldrich, A3854; 1:5,000; 30 min, RT)  as a housekeeping protein. Images were 
analysed using ImageLab Software™ v6.0 (Bio-Rad). The results were expressed as relative band 
density (RBD) obtained from the proportion of the RBD of the protein of interest and the RBD of the 
respective β-actin.  
 
2.13. Quantitative PCR (qPCR) 
2.13.1. Introduction 
Quantitative polymerase chain reaction (qPCR) involves the amplification and quantification of DNA. 
The conventional PCR technique only amplifies a target gene, whereas qPCR accurately quantifies 
the amount of target genes expressed. 
The qPCR amplification procedure involves three controlled steps that are performed at different 
temperatures in repeated cycles. Step 1 involves denaturation of the double-stranded DNA template at 
(90 - 100°C) to produce single-stranded DNA. The synthesis of cDNA requires various reagents and 
buffers (Table 2 & Table 3). Step 2 involves the annealing of complimentary primers to the target 
DNA sequence at temperatures dependent on the primer. Step 3 is extension in which Taq polymerase 
elongates the annealed primer at 72°C by adding nucleotides. These steps are repeated to produce 
exponential copies of the original DNA fragment (Table 4 & 5). 
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The quantity of the target genes expressed is detected using SYBR Green. A SYBR Green dye binds 
DNA and produces a fluorescent signal that can be detected and quantified (Fig 2.10).  
 
Figure 2.10 Overview of the qPCR steps (Adapted from (Kuang et al., 2018)). 
2.13.2. RNA isolation 
RNA was isolated from control and KA treated HepG2 cells as per (Chuturgoon et al., 2014). 
Following 24 h KA-treatment, cells were washed once with PBS and thereafter, 500 µl Qiazol and 
PBS were added and incubated (5 min, RT). Cells were mechanically scraped and transferred into 1.5 
ml microcentrifuge tubes and stored overnight (-80ºC). Chloroform (100 µl) was added, and 
centrifuged (12,000 x g, 10 min, 4ºC). The supernatant was removed, and to the pellet, isopropanol 
(250 µl) was added and stored overnight (-80ºC). Thawed samples were centrifuged (12,000 x g, 20 
min, 4ºC). The supernatant was discarded, and the pellet was washed with ethanol (75%) and 
centrifuged (7,400  x g, 15 min, 4ºC). Following the removal of ethanol, RNA pellets were air-dried 
(30 min, RT). The dried pellets were resuspended in nuclease-free water (15 µl) and stored at -80ºC.  
2.13.3. RNA Quantification 
The RNA was quantified using the Nanodrop 2000 spectrophotometer (ThermoScientific, Waltham, 




2.13.4. cDNA synthesis for mRNA 
For mRNA expression, cDNA was synthesized using the Maxima™ H Minus strand cDNA synthesis 
kit (ThermoFisher Scientific, K1652) (Table 2). The thermocycler conditions for cDNA synthesis 
were as follows: 25ºC for 10 min, 50ºC for 15 min, 85ºC for 5 min. 
 
Table 2. Reaction volume and components of the Maxima™ H Minus strand cDNA synthesis kit 
Component One reaction volume 
10 mM dNTP mix 1 µl 
Oligo (dT) primer (pmol) 0.25 µl 
Nuclease-free water 12.75 µl 
5× RT buffer 4 µl 
Maxima H minus enzyme mix 1 µl 
Template DNA 1 µl 
TOTAL 20 µl 
 
2.13.5 cDNA synthesis for miRNA 
For miRNA expression, cDNA was synthesized using the miScript II RT kit (Qiagen, 218161) as per 
manufacturers' instruction (Table 3). The thermocycler conditions for cDNA synthesis were as 
follows: 37ºC for 60 min, 95ºC for 5 min, 4ºC for 5 min. 
Table 3: Reaction volumes and components of iScript II RT kit used to synthesise cDNA for 
miRNA expression analysis 
Component One reaction (µl) 
5 x miScript HiFlex Buffer 4 µl 
10 x miScript Nucleics Mix 2 µl 
RNAse free water 11 µl 
miScript RT mix 2 µl 
RNA template 1 µl 
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TOTAL 20 µl 
 
2.13.6 mRNA expression 
The mRNA expressions of GPx, NFκB, and IκB were investigated using the PowerUp™ SYBR™ 
Green Master mix (ThermoFisher Scientific), as per manufacturers instruction. Primers for the 
forward and reverse sequences are presented in Table 5. Reaction volumes were prepared as follows;  
Table 4: qPCR reaction mix (PowerUp™ SYBR™ Green Master mix) 
Component One reaction volume/ volume per well. 
Sso advanced Universal SYBR Green Supermix 5 µl 
RNAse free water 2 µl 
Sense primer (25 µM) 1 µl 
Anti-sense primer (25 µM) 1 µl 
cDNA 1 µl 
TOTAL 10 µl 
 
CFX96 Touch™ Real-Time PCR Detection System (BioRad) was used to amplify samples. Cycling 
conditions were as follows: initial denaturation (8 min, 95ºC) followed by 40 cycles of denaturation 
(15s, 95ºC); annealing (40s, temperature was assessed based on the gene of interest (Table 5)) and 
extension (30s, 72ºC). Glyceraldehyde-3-Phosphate dehydrogenase (GAPDH), a house-keeping gene, 
was used to normalise mRNA expression. 
Table 5: The primer sequences and annealing temperatures used for mRNA expression 
Primer Sequence Annealing 
temperature (ºC) 
GPx Forward (5’-GACTACACCCAGATGAACGAGC-3’) 
Reverse (5’-AATCCCCAGCAGTGGAATAAGG-3’) 
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IκBα Forward (5’-CACTCCATCCTGAAGGCTACCAAC-3’) 
Reverse(5’-CACACTTCAACAGGAGTGACACCAG-3’) 
64 
GAPDH Forward (5’-TCCACCACCCTGTTGCTGTA-3’)  
Reverse (5’-ACCACAGTCCATGCCATCAC-3’) 
Same as gene of 
interest 
 
2.13.7. miRNA Gene expression 
The expression of miR-29a, miR-29b, and miR-155 were analysed using the miScript SYBR Green 
PCR kit (Qiagen, 218073) and 10X miScript primer assays (Qiagen, Hilden, Germany) as per 
manufacturers' instruction. The thermocycler conditions were as follows; initial activation (15 min, 
95ºC), denaturation (15 sec, 94ºC), annealing (30 sec, 55ºC), and extension (30 sec, 70ºC) for 40 
cycles. Human RNU6 (MS000033740) was used as a housekeeping gene to normalise miRNA 
expression. 
2.13.8. Analysis of data for mRNA and miRNA expression 
The relative mRNA expression change was assessed using the method described by (Livak and 
Schmittgen, 2001). The method represents the fold change relative to the control as 2
-∆∆Ct
. All qPCR 
data were analysed using Bio-Rad CFX Manager™ Software version 3.1. 
2.14. 8-OHdG Enzyme-linked immunosorbent assay (ELISA) 
2.14.1. DNA isolation 
2.14.1.1. Introduction 
A cell lysis solution was added to HepG2 cells to obtain crude DNA. The cell lysis solution was made 
up of EDTA (pH 8), SDS (0.1%), and Tris-Cl. EDTA is a chelation agent used due to its high affinity 







could inhibit the degradation of DNA. SDS is used as an anionic detergent to lyse the cell 
membranes and nucleus to enable the release of DNA. The Tris-Cl is positively charged and plays a 
role in stabilizing the repellent charges present in negatively charged helices (El-Ashram et al., 2016). 
2.14.1.2. Protocol 
Cells were treated with KA for 24 h, treatments were removed and the cells were washed three times 
with PBS. The PBS was discarded, and the Cell Lysis solution was added and incubated for 15 min at 
RT. The cells were mechanically scraped with a cell scraper until a homogenous solution was 
obtained. In a fume hood, potassium acetate solution (600 µl) was added and the samples were invert 
mixed for 8 min. The solution was vortexed and centrifuged for 5 min at 13,000 rpm at RT. The 
supernatant was decanted, and isopropanol (600 µl) was added. The solution was invert mixed and 
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subsequently centrifuged for 5 min at 13,000 rpm at RT. A white pellet was obtained, and careful 
consideration was taken not to disturb DNA when removing the isopropanol. Ethanol (300 µl) was 
added to the pellet and centrifuged at 13,000 rpm for 5 min at RT. The ethanol was decanted and the 
DNA pellet was air dried (15 min, RT). To the dry pellet, DNA hydration solution (TE buffer) [10 
mM EDTA (pH 8), 100mM Tris-Cl (pH 7.4) and dH2O] was added, and the samples were heated at 
65ºC for 15 mins. Once heated, the tubes were allowed to cool for 15 min at RT and stored at -20ºC.   
2.14.2. Standardisation and quantification  
Crude DNA concentration was quantified using the Nanodrop 2000 spectrophotometer 
(ThermoScientific, Waltham, USA). All samples were standardised to 100 ng/µl in TE buffer (150 µl) 
and used for the ELISA procedure.  
2.14.3. Enzyme-linked immunosorbent assay (ELISA) 
2.14.3.1. Introduction 
ELISA is based on the interaction between an antigen and antibody. Antibodies are produced by B-
cells in leukocytes and play a crucial role in the body’s immune response. Antigens form part of a 
group that consists of nucleic acids, proteins, peptides, and secondary metabolites (Sakamoto et al., 
2018). ELISA exploits this characteristic of antibodies and antigens in a highly specific and selective 
technique. ELISA is a five-step procedure (Fig 2.11). The method relies on the adsorption of antigens 
or antibodies onto a solid phase. The first step involves  antigens or antibodies coating on a 
polystyrene plate. The second step is the addition of samples to the wells to be captured by the 
antibodies. The third step requires the detection of antibody-antigen reaction is visualised using 
enzymes linked to antibodies such as horseradish peroxidase (HRP) (Sakamoto et al., 2018). The 
fourth step involves the addition of the HRP substrate (3,3’,5,5’- Tetramethylbenzidine, TMB), which 
forms a coloured complex with HRP which is visualised using a spectrophotometer. The last step 
stops the reaction using a stop solution (sulfuric acid) and data is analysed to determine the 
concentration of target molecule in the samples.  
2.14.3.2. Protocol 
Preparation of 8-OHdG standards were prepared by completing a serial dilution of 7 concentrations [ 
60, 30, 15, 7.5, 3.75, 1.875, and 0.94 ng/ml]. To a micrcentrifuge tube, 500 µl sample diluent is added 
and 250 µl into a second microcentrifuge tube. To the first microcentrifuge, 3 µl of 8-OHdG standard 
stock (10 µg/ml) was added. The samples were serially diluted to obtain the required concentrations. 
Briefly, standards (50 µl), zero standard, and isolated DNA samples (100 ng/ml) were added in 
duplicate in the 96-well microtiter plate. The anti-8-OHdG was diluted in antibody diluent, and 50 µl 
was added in the appropriate wells except for the blank.  The plates were covered and incubated at RT 
for 1 h. The individual wells were aspirated and washed five times with wash buffer (300 µl) and 
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inverted on an absorbent paper to remove excess liquid.  A working solution comprises of the anti-
mouse antibody and diluted in HRP diluent as per manufacturers' instruction. The working solution 
(100 µl) was pipetted into each well, and incubated (1 h, RT). Each well was aspirated and washed 
five times (300 µl, RT) and inverted to remove excess liquid. TMB substrate solution (100 µl) was 
added to each well and incubated (15 min, RT) in the dark. Following incubation, stop solution (100 
µl) was added to each well. The absorbance was read at a wavelength of 450 nm on a 
spectrophotometer. 
The average net optical density (OD) was calculated as follows; 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑒𝑡 𝑂𝐷 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑂𝐷 − 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑏𝑙𝑎𝑛𝑘 𝑂𝐷 
 
Absorbances were used to for the construction of a standard curve (average net OD standards versus 
concentration standards) from which the concentration of 8-OHdG was calculated.   
 
Figure 2.11 The principle of ELISA (prepared by author) 
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2.15. Statistical analysis 
The data were analysed using GraphPad Prism V5.0 Software (GraphPad Prism Software Inc.). One-
way analysis of variance (ANOVA) followed by Tukey multiple comparison tests (95% CI) was used 
to present data to determine statistical significance. The data was represented as mean ± standard 





















3.1. Mitochondrial output in HepG2 cells 
MTT and crystal violet assay was used to determine cell viability and mitochondrial output (0-12.67 
mM KA). KA dose-dependently decreased HepG2 cell viability with half a maximal inhibitory 
concentration (IC50) of 8.02 mM (Fig 3.1A). Furthermore, a significant decline in cell viability was 
observed at 4.22 and 12.67 mM KA (Figure 3.1B, p < 0.0001); these concentrations were used for all 
subsequent assays. 
 





































Figure 3.1 KA dose-dependently decreased HepG2 cell viability as depicted using the MTT 





3.2. Kojic acid induced cell death in HepG2 cells 
The activities of caspases 9, 8, and 3/7 and LDH leakage were assessed to determine cell death in 
HepG2 cells. KA upregulated the activity of the initiator caspase 9 (p < 0.0001, Fig 3.2A) and caspase 
8 (p = 0.0003, Fig 3.2B) at all concentrations compared to the control. The activity of the executioner 
caspase 3/7 was significantly increased by the 4.22 mM KA but decreased by the 12.67 mM treatment 
(p < 0.0001, Fig 3.2C). The LDH results indicate that KA at 4.22mM was decreased and 8.02 mM 
was significantly decreased whereas, 12.67 mM KA caused significant membrane damage (p < 
0.0001, Fig 3.3). The decrease in caspase 3/7 activity, as well as the increase in LDH 
leakage/membrane damage strongly suggests that necrosis is the mode of cell death. 





















































































































Figure 3.2 The effect of KA treatment on caspase activities of 9 (A), 8 (B), and 3/7 (C) in HepG2 
cells (*p<0.05, **p<0.001, ***p<0.0001) (n = 3) 






















Figure 3.3 The effect of KA on LDH leakage/membrane integrity in HepG2 cells  (**p < 0.001) 
(n = 3) 
3.3. Assessment of oxidative stress  
To confirm cell death induction due to stress responses, macromolecules, and ATP were assessed in 
HepG2 cells following KA treatment. ATP levels were not increased at 4.22 mM and 8.02 mM 





KA treatment altered the antioxidant status in HepG2 cells. KA significantly increased extracellular 
MDA production- a by-product of lipid peroxidation (p < 0.0001, Fig 3.5A) relative to the control. 
The increase of lipid peroxidation suggests the presence of oxidative stress. The markers of lipid 
peroxidation, such as 4-HNE, have the ability to form an adduct with DNA resulting in DNA breaks. 
Although lipid peroxidation markers were upregulated, it was found that KA did not induce a 
significant increase in 8-OHdG (p = 0.0025, Fig 3.5B). Protein carbonyls were assessed in KA-
exposed cells compared to the control. Protein oxidation was significantly decreased in KA-exposed 
cells (p < 0.0001, Fig 3.5C). 




























Figure 3.4 Intracellular ATP levels in HepG2 cells for 24h (***p<0.0001) (n = 3) 



































































Figure 3.5 The effect of KA on cellular oxidation in HepG2 cells. KA increased (A) extracellular 
MDA concentration, and decreased (B) 8-OHdG and (C) Protein carbonyl concentrations after 
24 h treatment (*p<0.05, **p<0.001, ***p<0.0001) (n = 3) 
3.4. Antioxidant responses  
Antioxidant response factors, Nrf 2 and p-Nrf 2 were downregulated significantly by KA (12.67 mM). 
At concentrations of 4.22 and 8.02  mM KA, Nrf 2 (p = 0.0002, Fig 3.6A) and p-Nrf2 (p < 0.0001, 





CAT, which aids in detoxification of peroxides, was downregulated following KA treatment (p = 
0.0002, Fig 3.6C).  The expression of GPx was investigated using qPCR to validate the occurrence of 
oxidative stress. GPx transcript levels were upregulated at 4.22 mM (1.51 fold) and 8.02 mM (1.07 


























Figure 3.6 The effect of KA on antioxidant expression of total Nrf2 (A), p-Nrf2 (B), CAT (C), 
GPx mRNA in HepG2 cells (*p<0.05, **p<0.001, ***p<0.0001) (n = 3) 
3.5. Immune response by MAPK proteins 
JNK1/2 and p38 are stress-activated protein kinases (SAPK) and play a role in cell regulation, 
inflammation, and apoptosis. MAPK proteins were assessed using Western blot to determine the 
immune response to KA. The expression of JNK1/2 was downregulated by KA relative to the control 
(p < 0.0001, Fig 3.7A & B). The protein expression of p38 was significantly increased at 





Figure 3.7  Immune response by MAPK proteins following KA-exposure (*p<0.05, **p<0.001, 
***p<0.0001). A. JNK1, B. JNK2, C. p38 (n = 3) 
3.6. Inflammatory response in HepG2 cells 
In the presence of toxic insults, inflammatory markers play a key role in cell regulation. Sirt1 acts as 
an inhibitor of inflammation by decreasing NFκB and AP-1 expression. Phosphorylated - Sirt1 
expression was significantly downregulated by KA relative to the control (p < 0.0001, Fig 3.8A).  AP-
1 expression was elevated by KA (p = 0.0003, Fig 3.8 B).  
Decrease in p-Sirt1 expression resulted in the increase of total NFκB protein expression (p < 0.0001, 
Fig 3.8C). However, NFκB pathway was not activated reflected in a decrease in phosphorylated-
NFκB expression. The decrease of activated NFκB was proportional to dose concentration (p < 





expression was decreased at 4.22 mM (0.82 fold), 8.02 mM (0.24 fold); however, at 12.67 mM (1.02 
fold) was unchanged relative to the control (Fig 3.9A). Notably, both protein and gene expression 
showed a significant decrease in NFκB expression at 8.02 mM. Similarly, IκB expression was 
decreased at 8.02mM. IκB expression was increased relative to the control at 4.22 and 12.67 mM (p < 






Figure 3.8  Protein expression of inflammatory markers, p-Sirt1 (A), AP-1 (B), NFκB (C) and p-














































Figure 3.9 Gene expression of inflammatory markers NFκB and IκB in HepG2 cells following 
KA-treatment (**p<0.001, ***p<0.0001) (n = 3) 
3.7. MiRNA expression involved in oxidative stress and immune response in HepG2 cells 
Following treatment, the gene expression of miRNA-29a was upregulated significantly at 12.67 mM 
(p = 0.0002, Fig 3.10A). MiRNA-29b expression was increased following KA-treatment (p = 0.0009, 

































Figure 3.10 MiRNA expression in HepG2 cells following KA-treatment (*p<0.05, **p<0.001, 










KA is found in a many food and beauty products. According to the U.S. Food and Drug 
Administration (FDA), A. oryzae (koji) is classified as generally regarded as safe (GRAS), although 
the nutritional benefit has not been thoroughly studied (Hamajima et al., 2016). In terms of skin-
lightening purposes, the FDA has not approved KA for use in pharmaceutical products (Belsito et al., 
2009). Studies pertaining to the toxicity of KA in the human liver are limited. The applications of KA 
in skin lightening have drawn attention to its toxicity on skin cells in humans and animals (Kim et al., 
2003, Lajis et al., 2012). KA is ingested in fermented food products, and therefore organs involved in 
the metabolism and excretion of toxins need to be further studied. The present study evaluated the 
effect of KA in key biochemical processes on HepG2 cells.  
Cell viability assays were carried out to determine the effect of KA on human liver cells. KA 
decreased cell viability in a dose-dependent manner, more significantly at high doses (12.67 mM) (Fig 
3.1A & B). The MTT assay did not show a significant decrease in cell viability; however, significant 
cell death was observed in the Crystal Violet assay. The result suggests no significant mitochondrial 
dysregulation (MTT assay) due to KA treatment, with the exception of 12.67 mM. Weak acids, such 
as KA, are known to inhibit growth by lowering the cellular pH. In the cytoplasm, the un-dissociated 
acid molecules pass through the plasma membrane by diffusion, depending on the molecule's 
lipophilicity. The acids dissociate into charged anions and protons. Some acids cannot pass through 
the plasma membrane and accumulate in the cytoplasm. The cytoplasm's acidification inhibits 
processes such as metabolism, leading to a decrease in cell viability (Stratford and Anslow, 1998, 
Kundukad et al., 2020).  
To confirm cell death, apoptosis activating caspases -9, -8, and 3/7 and LDH leakage/membrane 
integrity were assessed. Positive results for apoptosis initiation were reflected by an upregulation of 
caspase-8, -9, and -3/7 (Fig 3.2).  In agreement with previous studies, KA-induced apoptosis in HeLa 
cells in response to oxidative stress stimulated by copper-induced apoptotic agents (Chen et al., 2013). 
KA derivatives have copper-chelating properties that initiate apoptosis in HepG2 cells (Oncul et al., 
2019). However, in the present study, KA itself has shown increased caspase -3/7, -8, and -9 activity 
at lower concentrations (4.22 and 8.02 mM),  leading to cell apoptosis. It was also observed that there 
was a significant decrease in LDH levels suggesting no leakage and damage to cellular membranes 
(Fig 3.3). Interestingly at 12.67 mM, caspase -8 and -9 and executioner caspase -3/7 was not 
activated. However, LDH levels were increased, suggesting a decrease in cell viability due to the high 
concentration of KA damaging to the cellular membrane leading to necrosis.  
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Cellular metabolism efficiency is reliant on the supply of ATP that is produced in the mitochondria. 
The mitochondria are organelles responsible for the generation of ATP via the OxPHOS (Zhang et al., 
2018). A high density of mitochondria is essential for the high metabolic activity of the liver. A 
decline in cell viability suggests possible dysregulation on the mitochondrial level. The majority of 
ROS production occurs during mitochondrial respiration, making the mitochondria susceptible to 
damage (Ott et al., 2007). KA significantly increased ATP production (Fig 3.4). “Stress signals” are 
interpreted by the increase of ATP that mediates for downstream signalling. KA is known to increase 
ATP in the case of injury in Hypsizygus marmoreus (Zhang et al., 2017). Necrosis is an ATP-
independent mode of cell death however, cancer cells have the ability to utilise LDH to aerobically 
metabolise ATP. This could account for the increase of ATP at 12.67 KA. To date, there has been no 
study evaluating the change in ATP levels following exposure to KA treatment in human cells. 
KA increased MDA production in HepG2 cells, indicative of the occurrence of oxidative stress (Fig 
3.5A). KA elevated MDA levels significantly in the liver of iron-loaded Wistar rats and did not show 
any protective effect attributed to KA’s chelating ability (Kotyzova et al., 2004). The alteration in pH 
results in enzyme activity changes, reaction rates, protein stability, and nucleic acid structure 
(Kundukad et al., 2020).  
Due to KA's weak acid properties, protein and DNA damage was assessed. DNA plays an important 
role in information transfer; hence mutations can lead to pathologies such as cancer (Yin et al., 1995). 
An analysis on the most common DNA lesion, 8-OHdG was investigated. The data suggests a slight 
increase in the concentration of oxidative lesions; however, the result was statistically insignificant 
(Fig 3.5B). Genotoxic studies in vivo found that 8-OHdG oxidative adducts were not significantly 
increased in the thyroid of rats. The liver, colon, and stomach were further analysed to confirm the 
result and found no significant increase in the concentration of oxidative lesions in vivo correlating 
with the in vitro results obtained (Higa et al., 2007, Tamura et al., 2006). Studies into KA concerning 
its ability to form tumours in in vivo and in vitro models have displayed conflicting results. However, 
an attribute of KA highlighted by research is its anti-carcinogenic properties. DNA lesions have been 
found to be a factor leading to carcinogenesis. The highest treatment concentration decreased 8-
OHdG levels relative to the control, correlating with this deduction. Protein carbonyl concentrations 
were investigated to determine KA’s ability to oxidise proteins. A significant decrease in protein 
carbonyls (Fig 3.5C) relative to the control was observed. KA did not exert toxic effects on DNA and 
protein.  
Mammalian cells have defence mechanisms to ensure homeostasis of the intracellular environment by 
scavenging ROS (Basak et al., 2017). The production of ROS initiates the activation of regulatory 
proteins to minimise cellular damage. Nrf2 is responsible for cellular defence mechanisms by the 
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induction of the phase 2 responses. This process is dependent on the dissociation of KEAP-1, a 
repressor that contains zinc bound to reactive cysteine thiols and facilitates the detection of ROS and 
electrophiles. The phosphorylation of Nrf2 (p-Nrf2) leads to an increase in stability and activity 
(Nguyen et al., 2009). KA has the potential to target the zinc found between Nrf2 and KEAP-1, hence 
facilitating the release of Nrf2. Results showed an increase in Nrf2 and p-Nrf2 expression (Fig 3.6A 
& B), suggesting KA chelation properties may play a role in the release of Nrf2 from KEAP-1. Nrf2 
is a mediator of the anti-apoptotic protein Bcl 2 in stress-induced apoptosis. The increased in p-Nrf2 
expression by KA may have occurred due to persistent oxidative stress. However, the increase in Nrf2 
expression could have been insufficient due to apoptotic proteins being initiated, resulting in the 
release of cytochrome c into the cytosol and encouraging apoptosome formation.   
Nrf2 is a transcription factor that activates ARE, a protein found in antioxidants such as CAT and 
SOD2 (Nguyen et al., 2009). The cell's defence is the neutralisation of free radicals by reducing 
peroxides to water and oxygen facilitated by antioxidant enzymes, namely, CAT and SOD2 (Basak et 
al., 2017, Zhang et al., 2017).  The protein expression of CAT was downregulated following treatment 
with KA, but more significantly at 12.67 mM. The amount of MDA-TBA adducts produced correlates 
with the hindrance of cellular antioxidant response and lipid peroxidation (Fig 3.6C). This is in 
agreement with previous studies in which KA deactivated regulatory proteins, CAT, in the liver and 
kidney of rats (Kotyzova et al., 2004).  GPx functions in reducing peroxides and oxidises glutathione 
to glutathione disulphide. Gene expression of GPx revealed an increase at KA concentrations with 
high MDA levels (4.22 and 8.02 mM) (Fig 3.6D).  
Cells respond to stimuli by the activation of the MAPK signalling pathway in order to facilitate for an 
antioxidant response, inflammation, cell survival, and cell death (Cuenda and Rousseau, 2007, 
Shaulian and Karin, 2002, Weston and Davis, 2002, Kammeyer and Luiten, 2015). KA's role in the 
inhibition of tyrosinase activity by copper's chelation draws attention to the MAPK kinase proteins. 
The expression of MAPK proteins that mediates for cellular regulation, namely JNK1/2 and p38, were 
investigated to elucidate the cell's response to KA toxicity. The MAPK p38 and JNK1/2 proteins play 
a role in apoptosis, inflammation, and cytokine production (Morrison, 2012). JNK1/2 molecules are 
activated by DNA damage and oxidative stress (Sun et al., 2009). Additionally, JNK regulates the 
anti-apoptotic protein, Bcl-2 (Dhanasekaran and Reddy, 2008). The relationship is in agreement with 
the present study results as shown by the decrease of JNK1/2 ineffectively inhibiting Bcl-2 hence 
encouraging apoptosis (Fig 3.7A & B). p38 is a stress-activated protein kinase initiated by upstream 
MAPK signalling. KA was found to upregulate MAPK expression in HeLa cells (Chen et al., 2013), 
which is in agreement with the results obtained for p38 in HepG2 cells (Fig 3.7C). Prolonged 
activation of this pathway can lead to cell death due to the presence of ROS (Redza-Dutordoir and 
Averill-Bates, 2016, Ott et al., 2007). Stress signal detection is carried out by JNK1/2 and p38, which 
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initiate cell death activation and decrease cell proliferation (Ayala et al., 2014). This suggests the 
involvement of the MAPK pathway in response to ROS following KA treatment in HepG2 cells. 
Inflammation has been implicated in the initiation and progression of diseases. Key biomarkers 
involved in the NFκB pathway were evaluated to determine the effect of KA-treatment on 
inflammation in HepG2 cells (Fig. 3.8 & 3.9). Sirt1 possesses protective properties against oxidative 
stress by inhibiting NFκB and AP-1 expression (Becatti et al., 2018, Xie et al., 2013a). The expression 
of phosphorylated-Sirt1 was downregulated by KA (Fig 3.8A). AP-1 is made up of several proteins, 
namely Fos, Jun, Maf, and ATF. Sirt-1 decreases c-fos/c-Jun acetylation resulting in decreased 
transcription of AP-1. Therefore decreased Sirt-1 expression will cause an increase in AP-1 and NFκB 
expression. The study found an increase in AP-1 expression (Fig 3.8B). AP-1 plays a role in COX-2 
inflammatory responses (Xie et al., 2013a). Total NFκB expression was increased following KA-
treatment with the exception of 8.02 mM; however, phosphorylated-NFκB expression was decreased 
(Fig 3.8C & D). Despite the increase in NFκB expression, activation of NFκB and transcription of 
inflammatory genes was decreased by KA. The results correlate with KA anti-inflammatory 
properties illustrated in in vitro studies in other cell lines (Moon et al., 2001, Ahn et al., 2003). 
Similarly, gene expression of NFκB was decreased at 8.02 mM (Fig 3.9A). Gene expression of IκB 
was increased with the exception of 8.02 mM (Fig 3.9B). Due to the trend observed, the results 
suggest a potent inhibition of the inflammation pathway NFκB by KA at 8.02 mM.  
MicroRNA (miRNA) is a class of post-transcriptional repressors of gene expression (Reinhart et al., 
2000). KA significantly increased miRNA-29a expression at the 12.67 mM concentration. At 
12.67mM KA apoptosis and inflammation did not occur (Fig 3.10A). The result is in agreement with 
literature which states miRNA-29a exerts anti-apoptotic effects on cells and downregulates NFκB 
expression in miRNA-29a transgenic mice.   
MiRNA-29b dysregulation plays a role in fibrosis pathogenesis in C57BL/6 mice (Su et al., 2019). 
Moreover, miRNA-29b regulates oxidative stress, decreases cell viability, and increased apoptosis 
(Hou et al., 2017, Engedal et al., 2018). MiRNA-29b was shown to negatively regulate Sirt1 in 
ovarian cancer cells (Hou et al., 2017). MiRNA-29b has pro-apoptotic properties. The miRNA-29b 
expression was increased at concentrations shown to undergo apoptosis (Fig 3.10B).  
The miRNA control of oxidative stress and apoptosis was assessed by analysing miRNA-155 
expression in treated HepG2 cells. MiRNA-155 suppresses antioxidant response by SOD2 and CAT, 
promoting ROS generation. Regulation of miRNA-155 expression was found to be carried out by 
NFκB and MAPK signalling (Wang et al., 2015). However, NFκB is also a target of miRNA-155 by 
controlling IKKβ and IKKε expression (Ma et al., 2011). This results in the repression of NFκB 
activation which is consistent with the increased miRNA-155 expression and decreased NFκB 
expression. MiRNA-155 also stimulated cell proliferation in pancreatic cancer cells (T-rex and K-ras 
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cells) by the inhibition of FOXO3a (Wang et al., 2015). Hence KA upregulated miRNA-155 
expression at 4.22 mM; however, at higher concentrations, no significant changes were observed (Fig 
3.10C). Notably, the most significant elevation in MDA levels and miRNA-155 occurred at 4.22 mM 




From the data obtained, it can be determined that KA has cytotoxic potential in HepG2 cells. Studies 
show that KA at very low concentrations acts as an antioxidant (Saeedi et al., 2019). The 
concentrations found to cause oxidative stress was much higher than the KA content in cosmetics. 
HepG2 cells were susceptible to KA toxicity by inducing oxidative stress. The study found no 
significant DNA and protein damage at treated concentrations. On the contrary, KA has shown 
potential hepatic protective properties. MAPK proteins activate inflammatory pathways in the 
presence of oxidative stress. KA elevated stress-activated protein kinase p38 and decreased 
inflammatory biomarkers. 
The evaluation of cosmetic products was found to contain KA concentrations between 1-2%. The 
European Commission's Scientific Committee on Scientific Products (SCCP) determined a maximum 
allowed concentration of 1% in skincare products due to health concerns reflected in published work 
on the effect of thyroid and skin sensitisation (SCCP, 2008). KA use as a food preservative in seafood 
was found to have an approximate concentration of 0.25%-0.6% KA.  
In terms of ingestion, KA is a fermentation by-product in food and is found in small quantities. 
Previous research has found the LD50 dose in mammals to be 1g/kg (Brtko et al., 2004). The 
absorption and distribution of KA were found to be negligible from dermal penetration. Therefore 
metabolism of KA will significantly lower the distributed concentration of KA. 
In conclusion, the study illustrated that although oxidative stress and apoptosis was elevated, the 
effect on liver health in terms of DNA damage, protein oxidation and inflammation was minimal. 
Notably, the concentrations of the KA used to exert such effects were much larger than the average 
use and require further research through dermal and oral exposures. 
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CHAPTER 6 
LIMITATIONS OF THE STUDY 
KA's use in the beauty industry suggests varying exposure periods. The present study investigated cell 
viability due to KA exposures for 6h, 24h, and 48h. The study was carried out on an immortalised cell 
line in vitro; therefore, future studies need to be carried in an in vivo model to validate the in vitro 
study results.   
KA has weak acid properties that have a potential mitochondrial effect. HepG2 cell lines are a cancer 
cell line that minimizes dependence on the mitochondria; therefore, the mitochondrial output cannot 
conclusively be deduced until further studies are carried out. 
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APPENDIX A 
KA increased cell viability at concentrations (0-4.22 mM) following a 6h KA-treatment with the 
highest increase in cell viability at 4.22 mM (170.65%). A decrease in cell viability in comparison to 
4.22 mM, was observed at 5.63 -12.7 mM with the lowest cell viability percentage at 126.8% (Fig 4). 
There was no inhibition of cell viability observed relative to the control (p =0.0006). 



















Figure 4.1 KA increased cell viability as depicted using the MTT assay in HepG2 cells for 6h 
(*p<0.05, **p<0.001, ***p<0.0001) (n = 3) 
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APPENDIX B 
KA dose-dependently decreased cell viability of HepG2 cells following a 48h treatment (Fig 5). The 
data illustrates that KA is cytotoxic to cells with an IC50 = 7.2 mM. The IC50 was determined to be 
similar to that of the 24h treatment. Therefore, subsequent treatments were carried out at the 
determined 50% cell death concentrations for 24h. 

















Figure 5.1 KA dose-dependently decreased HepG2 cell viability as depicted using the MTT 
assay for 48h (IC50= 7.2 mM) 
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APPENDIX C 
BCA assay (Western Blot protein preparation) 
Figure 6.1 Standard curve obtained from BSA protein standard to determine the unknown 
concentrations of protein in samples 
Table 6. Standardisation of proteins used for Western Blot (Final volume = 200µl; 











CytoBuster (µl) Volume of 
Laemmli buffer 
(µl) 
0 1.976 1.550689 129.03 70.97 200 
4.22 2.2995 1.836365 108.7 91.3 200 
8.02 2.0945 1.655334 121.21 78.79 200 
12.67 1.9215 1.502561 133.33 66.67 200 
y = 1.1324x + 0.22 
























BSA concentration (mg/ml) 
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APPENDIX D 
BCA assay (Protein carbonyl preparation) 
Figure 7.1 Standard curve obtained from BSA protein standard to determine the unknown 
concentrations of protein in samples 
Table 7. Standardisation of proteins used for the protein carbonyl assay (Final volume = 300µl; 

















0 2.291 2.00829 149.3808 150.6192 300 
4.22 2.079 1.79629 167.0109 132.9891 300 
8.02 2.0855 1.80279 166.4087 133.5913 300 
12.67 2.1005 1.81779 165.0356 134.9644 300 
y = 0.8369x + 0.2366 
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APPENDIX E 
DNA isolation standardisation 
Table 8. Standardisation of DNA used for ELISA (Final volume = 150µl; concentration = 100 
ng/ml) 
Concentrations (mM) DNA stock (µl) TE buffer (µl) 
0 18.32 131.68 
4.22 11.34 138.66 
8.02 13.98 136.02 
12.67 13.21 136.79 
ELISA standard curve

















Figure 8 The 8-OHdG concentrations standards obtained from ELISA to extrapolate unknown 
concentration of DNA adducts in treatment samples 
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Table 9: Concentrations extrapolated from the 8-OHdG standard concentration graph 
Concentration of Treatment (mM)  Concentration of DNA damage (ng/ml) 
0 0.7315 
4.22 0.8872 
8.02 1.1702 
12.67 0.4937 
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APPENDIX F 
Turnitin Report 
